Development of Small Molecules as Chemical Probes for Understanding the Pathology of Alzheimer???s Disease by Lee, Misun
 
 
저 시-비 리- 경 지 2.0 한민  
는 아래  조건  르는 경 에 한하여 게 
l  저 물  복제, 포, 전송, 전시, 공연  송할 수 습니다.  
다 과 같  조건  라야 합니다: 
l 하는,  저 물  나 포  경 ,  저 물에 적 된 허락조건
 명확하게 나타내어야 합니다.  
l 저 터  허가를 면 러한 조건들  적 되지 않습니다.  
저 에 른  리는  내 에 하여 향  지 않습니다. 




저 시. 하는 원저 를 시하여야 합니다. 
비 리. 하는  저 물  리 목적  할 수 없습니다. 
경 지. 하는  저 물  개 , 형 또는 가공할 수 없습니다. 
I 
Development of Small Molecules 
as Chemical Probes for Understanding 

















Department of Chemistry 
 
Graduate School of UNIST 
II 
Development of Small Molecules 
as Chemical Probes for Understanding 









A thesis submitted to the Graduate School of UNIST 
in partial fulfillment of the requirements 
















Associate Professor Oh-Hoon Kwon 
III 
Development of Small Molecules 
as Chemical Probes for Understanding 





This certifies that the thesis of Misun Lee is approved. 
12. 03. 2018 
 
 
                      Signature 
 
 
                      ___________________________ 
                      Advisor: Associate Professor Oh-Hoon Kwon 
 
 
                    Signature 
 
 
                     ___________________________ 
                     Associate Professor: Mi Hee Lim 
 
 
                   Signature 
 
 
                    ___________________________ 




Alzheimer’s Disease (AD), responsible for most dementia cases, is one of the prevalent 
neurodegenerative diseases. Multiple features (e.g., neuroinflammation, accumulation of amyloid 
aggregates, dyshomeostasis of metal ions) have been implicated in the pathogenesis of AD, and such 
multifactorial nature impedes the investigation of the effective treatment of the disease. To elucidate the 
unrevealed biological actions linked with the pathogenesis and identify the remedy for the disease, 
many studies have been focused on devising and utilizing small molecules as chemical probes or 
potential therapeutics. In Chapter 1, we describe the development of a small molecule, 1, as a chemical 
agent for understanding the interconnection between neuroinflammation and amyloid-β (Aβ) peptides 
as well as a potential drug candidate against AD. By intervening in the inflammatory process of 
microglia, 1 could promote the microglial phagocytosis of Aβ and subsequently ameliorates cognitive 
defects in vivo. These results could provide an advanced insight to future discovery of effective anti-
neuroinflammatory drugs against neurodegeneration. In Chapter 2, a turn-on near-infrared (near-IR) 
fluorescent probe, 2, for imaging Aβ aggregates is introduced. The ability of 2 was evaluated to alter 
fluorescent response depending on the degree of Aβ aggregation, at the near-IR region, and its suitability 
for imaging Aβ aggregates under cellular environments. This work allows us to attain new perceptions 
to devise improved fluorescent probes with better specificity and bioapplicability, via further structural 
modifications. In Chapter 3, the design of small molecules capable of detecting metal ions in living 
cells is described. These studies present the capability of our molecules to monitor metal ions in living 
cells. Overall, our studies illustrate the utilization of small molecules to gain a better understanding of 
the pathogenic factors of interest, which will contribute to invention of chemical agents used for 
elucidating the pathology of AD. 
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per os, p.o.; 5 min administration; chalf-life (t1/2); dintrinsic clearance (CIint); emean (n = 3); fstandard 
deviation; gcoefficient of variation. (e) Escape latency time of vehicle- or 1-treated APP/PS1 mice 
(vehicle or 1) and wild-type mice (WT) in the Morris Water Maze (MWM) test. (f) Measurements of 
the crossing frequency and the time spend in target quadrant in the probe test. (g) Analysis of the 
amounts of Aβ plaques, detected by thioflavin-S (ThS), after the daily treatments of 1 for 2 months (2 
mg/kg/day; intraperitoneal, i.p.) in APP/PS1 mice starting at 7.5 months of age. Scale bars = 200 µm. 
All data analysis was done at 9.5 months of age. Animal number: (e and f) n = 10 for WT mice or 
vehicle-treated APP/PS1 mice and n = 10 for 1-treated APP/PS1 mice. (g) n = 4 for vehicle-treated or 
1-treated APP/PS1 mice. *P < 0.05; **P < 0.01; ***P < 0.001 by Student’s t test or One-way analysis 
of variance, Tukey’s post hoc test. All error bars indicate standard errors of mean (s.e.m.). 
 
Figure 1.2. 1H (400 MHz) and 13C (100 MHz) NMR Spectra of 1 in DMSO-d6.  
 
Figure 1.3. Behavioral tests of 1-treated APP/PS1 mice (1; 2 mg/kg/day; i.p.) compared to wild-type 
mice (WT) and vehicle-added APP/PS1 mice (vehicle). (a) Fearing conditioning test. (b) Open field test. 
(c) Light and dark test. 1-treated APP/PS1 mice (1). All data analysis was done at 9.5 months of age. 
Animal number: n = 10 for WT or vehicle-treated APP/PS1 mice; n = 10 for 1-treated APP/PS1 mice. 
*P < 0.05 by One-way analysis of variance, Tukey’s post hoc test. The bars denote mean ± s.e.m.  
 
Figure 1.4. Efficacies of 1 on Aβ species and cognitive defects in 5XFAD mice after the daily treatment 
of 1 or vehicle for 1 month (1 mg/kg/day; i.p.) at 4 months of age. (a) Escape latency time of vehicle- 
or 1-treated 5XFAD mice (vehicle or 1) and WT in the Morris water maze test. (b) Measurements of 
the crossing frequency and the time spend in target quadrant in the probe test. (c) Analysis of the 
amounts of 4G8-immunoreactive amyloid deposits measured from the hippocampal (hip), cortical (ctx), 
and thalamic (thl) areas of the brain in vehicle- or 1-treated 5XFAD mice (vehicle or 1). Scale bars = 
200 µm (white) and 500 µm (black). (d) Levels of total Aβ, soluble Aβ, insoluble Aβ, oligomeric Aβ 
and congophilic plaques in triplicate per sample. Animal number: (a and b) n = 17 for WT mice and n 
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Figure 1.5. Change in neuroinflammation upon treatment of 1 in wild-type (WT) and APP/PS1 mice. 
(a and b) Representative images and quantification of activated microglia (Iba1) and astrocyte (GFAP). 
Scale bars = 50 µm (c) Analysis of alteration in mRNA levels of pro- and anti-inflammatory cytokines 
after administration of 1 into WT mice (WT), vehicle-treated APP/PS1 mice (vehicle), and 1-treated 
APP/PS1 mice (1). Pro-inflammatory marker: TNF-α, IL-1β, IL-6, and iNOS, Immunoregulatory 
cytokine: IL-10, Anti-inflammatory marker: IL-4, TGF-β, and Arg1. All data analysis was done at 9.5 
months of age. Animal number: (a-c) n = 4 for WT mice and n = 4 for vehicle- or 1-treated APP/PS1 
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mice. *P < 0.05; **P < 0.01 by One-way analysis of variance, Tukey’s post hoc test. All error bars 
indicate s.e.m. 
 
Figure 1.6. Identification of the responsible cells upon incubation of Aβ42 with and without 1. (a) 
Analysis of mRNA levels of inflammatory cytokines in microglia by treatment of Aβ42 species with and 
without 1 or in astrocytes [grown by transferring the conditioned media (CM) harvested from the 
microglia] (n = 3 independent experiments). (b) Measurement of mRNA levels of inflammatory 
cytokines in astrocytes upon addition of Aβ42 species with and without 1 or in microglia (grown by 
transferring the CM harvested from the astrocytes) (n = 3 independent experiments). (c) Determination 
of mRNA levels of off/on signals in neurons with incubation of Aβ42 species with and without 1 or 
inflammatory cytokines in microglia (grown by transferring the CM harvested from the neurons) (n = 
3 independent experiments). Conditions: [Aβ42] = 10 µM; [1] = 10 µM; pro-inflammatory marker: TNF-
α, IL-1β, IL-6, and iNOS; immunoregulatory cytokine: IL-10; anti-inflammatory marker: IL-4, TGF-
β, and Arg1; off signals: BDNF, CD4, and CD200; on signals: CXCL10, CCL21, and MMP3. *P < 
0.05; **P < 0.01 by One-way analysis of variance, Tukey’s post hoc test. All error bars indicate s.e.m. 
 
Figure 1.7. Analysis of the microglial phagocytosis of Aβ and the activity of NLRP3 inflammasome-
related proteins in 1-treated APP/PS1 mice. (a) Colocalization of the microglia (Iba1, red) with Aβ 
aggregates (ThS, green) and quantification. Scale bars = 10 µm. 3D reconstruction from confocal image 
stacks. Scale bars = 10 µm. (b) Immunofluorescence images of Aβ aggregates (ThS, green) 
encapsulated within phagolysosome (Lamp1, blue) in microglia (Iba1, red) in the brains of vehicle- or 
1-treated APP/PS1 mice. Quantification of the microglial volume occupied by Lamp1(+) 
phagolysosomes, percent of the microglia containing Aβ-loaded phagolysosome, and Aβ encapsulated 
in phagolysosomes. Low magnification scale bars = 40 µm; high magnification scale bars = 10 µm. 3D 
reconstruction from confocal image stacks. Scale bars = 10 µm. (c) Morphology of microglia (Iba1, red) 
surrounding Aβ (ThS, green) in the cortex of vehicle- or 1-treated APP/PS1 mice. Scale bars = 10 µm. 
3D reconstruction from confocal image stacks. (d) Morphometric analysis of Aβ plaques in vehicle- or 
1-treated APP/PS1 mice. (e) Effects of 1 on the activity of NLRP3 inflammasome-related proteins. 
Wild-type mice (WT), vehicle-treated APP/PS1 mice (vehicle), and 1-treated APP/PS1 mice (1). All 
data analysis was done at 9.5 months of age. Animal number: (a-d) n = 3 for vehicle- or 1-treated 
APP/PS1 mice; (e) n = 4 for WT mice and n = 4 for vehicle-treated or 1-treated APP/PS1 mice. *P < 
0.05; **P < 0.01 by Student’s t test or One-way analysis of variance, Tukey’s post hoc test. All error 
bars indicate s.e.m. 
 
Figure 1.8. Effects of 1 on the aggregation of Aβ and the expression of Aβ-degrading enzymes. (a) 
Scheme of the (i) inhibition and (ii) disaggregation experiments. (b) Visualization of the size distribution 
of the resultant Aβ40 and Aβ42 species from (i) and (ii) by gel/Western blot using an anti-Aβ antibody 
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(b, i). Scale bars = 200 nm. Conditions: [Aβ40 or Aβ42] = 25 µM; [1] = 50 µM; 20 mM HEPES, pH 7.4, 
150 mM NaCl; 24 h; 37 °C; constant agitation. (d) Analysis of the levels of the enzymes (i.e., NEP, 
MMP9, and IDE) involved in Aβ degradation in wild-type mice (WT) and vehicle- or 1-administrated 
APP/PS1 mice (vehicle or 1). All data analysis was done at 9.5 months of age. Animal number: (d) n = 
4 for WT mice and n = 4 for vehicle- or 1-treated APP/PS1 mice. *P < 0.05 by One-way analysis of 
variance, Tukey’s post hoc test. All error bars indicate s.e.m. 
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Figure 2.8. Fluorescent responses of 2 towards (a) Aβ42 aggregates, generated by pre-incubation for 5 
h, and (b) ubiquitin. Conditions: [Aβ42] = 0.5, 1, 2, 5, and 10 µM; [ubiquitin] = 20 µM; [2] = 2 µM; 20 
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(0.3, 1, 1.3, 2, 5, and 10 h) Aβ40 (top) and Aβ42 (bottom) were obtained after 10 min incubation with 2. 
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Figure 2.11. Cytotoxicity of 2. Cell viability (%) of 5Y cells incubated with various concentrations of 
2 was calculated through the MTT assay. 2 was treated in 5Y cells and incubated for (a) 30 min and (b) 
24 h. The cell viability was determined relative to that of the cells treated with an equivalent amount of 
DMSO. Error bars indicate the standard error from four independent experiments. Conditions: [2] = 0.5, 
1, 5, 10, 20, and 50 µM (1% v/v DMSO). 
XII 
 
Figure 3.1. Fluorescence imaging of HeLa cells incubated with 3 and Al3+. Cells were pre-incubated 
with Al3+ for 20 min prior to addition of 3. Conditions: [3] = 25 µM, [Al3+] = 500 µM, 37 °C, 5% CO2. 
Scale bars = 50 µm. 
 
Figure 3.2. Fluorescence imaging of HeLa cells incubated with 4 and Zn2+. Cells were incubated with 
4 and Zn2+ for 5 min. Conditions: [4] = 10 µM; [Zn2+] = 1 mM; 37 °C; 5% CO2. Scale bars = 50 µm. 
 
Figure 3.3. Toxicity of 4 incubated in HeLa cells for (a) 5 min and (b) 24 h. 4 was treated to HeLa cells 
at various concentration (5, 10, 20, and 50 µM; 1% v/v DMSO). Cell viability (%) was determined by 
the MTT assay [MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] in comparison 
to that of cells treated with DMSO only (1% v/v). Error bars represent the standard error from three 
independent experiments. 
 
Figure 3.4. Fluorescence images of HeLa cells incubated with 5 followed by the addition of Zn2+. Cells 
were treated with 5 for 90 min prior to the introduction of Zn2+. Conditions: [5] = 25 µM; [Zn2+] = 0.5 




List of Schemes 
Scheme 2.1. Synthetic route to 2. 
 
Scheme 3.1. Proposed binding mode of 3 with Al3+. 
 
Scheme 3.2. Possible binding mode of the 4−Zn2+ complex. 
 
Scheme 3.3. Proposed binding mode of 5 with Zn2+. 
  
XIV 
List of Abbreviations 
AD    Alzheimer’s disease 
Aβ   Amyloid-β  
Near-IR   Near-infrared 
CNS    Central nervous system 
NLRP3   NACHT, LRR, and PYD domains-containing protein 3 
MTT    3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
BBB    Blood-brain barrier  
DMSO    Dimethyl sulfoxide  
NMR   Nuclear magnetic resonance 
WT    Wild-type 
MWM    Morris water maze 
ThS    Thioflavin-S 
s.e.m.   Standard errors of mean 
APP    Amyloid precursor protein  
PS1    Presenilin-1 
i.p.   Intraperitoneal  
Iba1   Ionized calcium-binding adapter molecule 1 
GFAP   Glial fibrillary acidic protein 
Lamp1   Lysosomal-associated membrane protein 1 
CM    Conditioned media  
TNF-α   Tumor necrosis factor-alpha 
IL-1β   Interleukin-1β  
IL-6   Interleukin-6 
iNOS   Inducible nitric oxide synthase;  
IL-10   Interleukin-10 
IL-4   Interleukin-4 
TGF-β   Transforming growth factor-β 
Arg1   Arginase 1 
CXCL10  Chemokine (C-X-C Motif) ligand 10 
CCL21   Chemokine (C-C Motif) ligand 21 
MMP3   Matrix metallopeptidase 3 
CD47   Cluster of differentiation 47 
BDNF   Brain-derived neurotrophic factor 
CD200   Cluster of differentiation 200 
XV 
NEP   Neprilysin 
MMP9   Matrix metallopeptidase 9 
IDE   Insulin degrading enzyme 
GAPDH   Glyceraldehyde 3-phosphate dehydrogenase 
ASC    Apoptosis-associated speck-like protein containing CARD 
Gel/Western blot  Gel electrophoresis and Western blot  
TEM    Transmission electron microscopy  
UV−Vis   Ultraviolet–visible spectroscopy 
DMF    Dimethylformamide 
NADPH   Dihydronicotinamide adenine dinucleotide phosphate  
CSF    Cerebrospinal fluid  
PCR   Polymerase chain reaction 
ELISA    Enzyme-linked immunosorbent assay 
ThT    Thioflavin-T  
GFP    Green fluorescent protein  
DAPI    4′,6-Diamidino-2-phenylindole  




A Small Synthetic Molecular Entity Capable of  














I thank Dr. Min Hee Park, Ju Youn Lee, Min Seock Jeong, Kang Ho Park, Seung Hoon Han, Professor 
Hee Kyung Jin, and Professor Jae-Sung Bae for in vivo studies employing APP/PS1 mice with data 
analysis; Mingeun Kim and Juhye Kang for characterization, gel/Western blot analysis, TEM, and cell 
studies; Geewoo Nam for writing; Eunyoung Tak, Min Sun Kim, and Professor Joo-Yong Lee for in 
vivo studies employing 5XFAD mice with data analysis. I carried out the preparation of reagents, 
gel/Western blot analysis, cell studies, analysis, organization of all data, and writing. I appreciate 




Neurodegeneration, defined as a progressive loss of neuronal structure and function, is the primary 
manifestation of many neurodegenerative diseases1. Increasing epidemiological evidence suggests that 
neuroinflammation, an innate immune mechanism of the central nervous system (CNS), is a major 
pathological contributor in neurodegeneration2-5. Microglia play a key role in this process, as they are 
the resident phagocytes in the CNS responsible for identifying and eliminating pathogens2,6-12. Under 
normal conditions, the microglial immune response balances opposing roles in which they can either 
excrete pro-inflammatory mediators, involved in cellular recruitment and removal of impaired neurons, 
or produce anti-inflammatory mediators, capable of promoting neuronal proliferation and synaptic 
plasticity2,10,11. In contrast, the persistent presence of pathologic triggers (e.g., neuronal injury and 
protein aggregates) results in the chronic activation and impairment of microglia2,7. Microglial 
dysfunction is often characterized by (i) elevated expression of neurotoxic pro-inflammatory mediators; 
(ii) decreased production of neurotrophic anti-inflammatory mediators; (iii) compromised ability to 
remove pathogens through the loss of phagocytic capacity2,7,9,10. The combined effects of such 
microglial anomalies incite negative neuronal consequences10, amplified through self-propagation and 
positive-feedback loops2,7. Therefore, microglial dysfunction is a potential target for drug discovery and 
may offer a therapeutic opportunity against neurodegenerative diseases, including Alzheimer’s disease 
(AD)2,7, Parkinson’s disease3, and amyotrophic lateral sclerosis4. 
AD is the most common form of dementia accounting for ca. 47 million cases in 2016, and the 
number of AD patients is projected to reach almost 131 million by 205013. The multifaceted 
etiopathology of AD involves a variety of pathological factors, such as neuroinflammation and 
amyloidogenic proteins, including amyloid-β (Aβ)14. Moreover, the intertwined pathology between 
neuroinflammation and Aβ has been recognized to be critical towards the development of AD7,15. Loss 
of the phagocytic ability upon microglial dysfunction significantly decreases Aβ clearance and the 
subsequent elevation of Aβ levels can induce microglial impairment through chronic activation2,9,16. 
This malignant cycle is a strong driving force of neurodegeneration17. Thus, an efficient and effective 
strategy for restoring microglial function is necessary to reestablish neuronal homeostasis in AD. 
Mounting research efforts have been dedicated to modulating microglial dysfunction with 
synthetic and repurposed chemical reagents18-21. Among the candidates, a synthetic NLRP3 (NACHT, 
LRR, and PYD domains-containing protein 3) inflammasome inhibitor, MCC950, exhibited restorative 
efficacy toward microglial dysfunction, promoting Aβ phagocytosis and improving cognitive function 
in vivo22,23. The aforementioned studies suggest that small molecules may be effective for regulating 
microglial dysfunction, but practical working examples are exceedingly rare. We report a novel 
neuroprotective compound, 1 (Figure 1.1a), as the smallest synthetic molecular entity capable of 
restoring cognitive defects to a significant extent by enhancing the microglial phagocytic clearance of 
Aβ aggregates in the brains of AD transgenic mice. We show that 1 downregulates the constituent 
3 
proteins of NLRP3 inflammasomes in vivo and subsequently lowers the production of the pro-
inflammatory mediators, caspase-1 and IL-1β, leading to the recovery of microglial function. Our 
studies substantiate the possibility of designing small and simple molecules for rectifying microglial 
dysfunction and boosting microglial phagocytic aptitude. The new neuroprotective reagent, 1, is a 
promising prototype of a remedial agent that can regulate neurodegenerative inflammation. 
 
1.2. Results and Discussion 
1.2.1. Design Rationale and Characterization of 1 as an Anti-Inflammatory Agent for 
Neuroprotection 
A small molecule, 1 (Figure 1.1a), was rationally chosen based on the molecular framework of 
acetaminophen, an antipyretic and analgesic drug with widely accepted clinical efficacy and safety24,25. 
Recent studies have increasingly supported acetaminophen’s neuroprotective activity involving the 
modulation of inflammatory pathways, apart from its well-known biological properties26-33. Cellular 
and in vivo investigations utilizing diverse cell lines and cognitively impaired animals reported 
neuroprotection by acetaminophen through the downregulation of overexpressed pro-inflammatory 
markers26-33. Based on its anti-inflammatory effects, we selected acetaminophen as the structural basis 
for designing a small molecule capable of controlling neuroinflammation. To obtain a more robust 
molecular structure (1; Figure 1.1a) than acetaminophen, a simple and straightforward structural 
modification was implemented to preemptively account for its potential chemical and metabolic 
instability (e.g., oxidative transformation)34 by replacing the phenol moiety with an acetamide 
functionality (Figure 1.2).  
Prior to in vivo evaluation, the bioapplicability of 1 was investigated by determining its 
cytotoxicity, microsomal stability, and blood-brain barrier (BBB) permeability. First, no significant 
toxicity was observed in murine Neuro-2a (N2a) neuroblastoma cells treated with 1 at concentrations 
up to 500 µM (Figure 1.1b). Second, the metabolic studies of 1 using human liver microsomes revealed 
its moderate metabolic stability [half-life (t1/2) > 60 min; intrinsic clearance (Clint) = 3.9; Figure 1.1c]. 
Lastly, the presence of 1 in the brains of CD1 mice after oral administration (10 mg/kg) indicated its 
potential to cross the BBB (Figure 1.1d). Together, 1 is determined to be suitable for in vivo assessment 






Figure 1.1. Overview of the studies presented in this work and in vivo efficacies of N,N'-p-
phenylenebisacetamide (1). (a) Design, chemical structure, and working principle of 1 for in vivo 
efficacies. (b) Cytotoxicity of 1. Cell viability (%) of N2a neuroblastoma cells incubated with various 
concentrations of 1 for 24 h was measured by the MTT assay [MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide]. The cell viability (%) was calculated relative to cells treated with an 
equivalent amount of DMSO 1% v/v). The bars indicate the standard error from triplicate experiments. 
(c) Metabolic stabilitya and (d) brain uptakeb of 1. aHuman liver microsomes; bCD1 mice; 10 mg/kg; 
per os, p.o.; 5 min administration; chalf-life (t1/2); dintrinsic clearance (CIint); emean (n = 3); fstandard 
deviation; gcoefficient of variation. (e) Escape latency time of vehicle- or 1-treated APP/PS1 mice 
(vehicle or 1) and wild-type mice (WT) in the Morris Water Maze (MWM) test. (f) Measurements of 
the crossing frequency and the time spend in target quadrant in the probe test. (g) Analysis of the 
amounts of Aβ plaques, detected by thioflavin-S (ThS), after the daily treatments of 1 for 2 months (2 
mg/kg/day; intraperitoneal, i.p.) in APP/PS1 mice starting at 7.5 months of age. Scale bars = 200 µm. 
All data analysis was done at 9.5 months of age. Animal number: (e and f) n = 10 for WT mice or 
vehicle-treated APP/PS1 mice and n = 10 for 1-treated APP/PS1 mice. (g) n = 4 for vehicle-treated or 
1-treated APP/PS1 mice. *P < 0.05; **P < 0.01; ***P < 0.001 by Student’s t test or One-way analysis 





Figure 1.2. 1H (400 MHz) and 13C (100 MHz) NMR Spectra of 1 in DMSO-d6.  
 
 
1.2.2. 1 Improves Cognitive Deficits in AD Transgenic Mice with Reduced Amounts of Aβ Species 
In vivo efficacy of 1 was first evaluated in APP/PS1 mice, an AD double transgenic mouse model that 
contains both mutant amyloid precursor protein (APP) and presenilin-1 (PS1) transgenes, characterized 
by increased production and accumulation of Aβ aggregates as well as notable cognitive impairment35. 
APP/PS1 mice (7.5 months of age) were subject to intraperitoneal (i.p.) administration of 1 or vehicle 
at 2 mg/kg/day for 2 months. After 30 days of treatment, the Morris Water Maze (MWM) test was 
carried out to examine the spatial learning and memory of wild-type (WT) and vehicle- or 1-treated 
APP/PS1 mice. As shown in Figure 1.1e, the vehicle-treated APP/PS1 mice, relative to WT mice, 
exhibited noticeably longer escape latencies, while 1-added APP/PS1 mice were able to locate the 
escape platform at time points comparable to those of WT mice. Such differences were especially 
notable from the 5th day of trials, at which point the escape latencies of vehicle- and 1-treated APP/PS1 
mice deviated by ca. 2-fold. In the probe trials conducted after 10 days of training, 1-administered 
APP/PS1 mice traversed the target location more frequently and stayed in the objective quadrant for 
longer periods compared to APP/PS1 mice injected with vehicle (Figure 1.1f). Interestingly, 1-treated 
APP/PS1 mice demonstrated similar results to WT mice, suggesting the restoration of spatial cognition. 
In the case of the locomotion and spontaneous activity of APP/PS1 mice, 1 did not induce significant 





Figure 1.3. Behavioral tests of 1-treated APP/PS1 mice (1; 2 mg/kg/day; i.p.) compared to wild-type 
mice (WT) and vehicle-added APP/PS1 mice (vehicle). (a) Fearing conditioning test. (b) Open field test. 
(c) Light and dark test. 1-treated APP/PS1 mice (1). All data analysis was done at 9.5 months of age. 
Animal number: n = 10 for WT or vehicle-treated APP/PS1 mice; n = 10 for 1-treated APP/PS1 mice. 
*P < 0.05 by One-way analysis of variance, Tukey’s post hoc test. The bars denote mean ± s.e.m.  
 
  
The ability of 1 to restore cognitive function in AD transgenic mice was further confirmed 
employing 5XFAD mice, an AD transgenic mouse model overexpressing mutant human APP695 
[K670N/M671L (Swedish), I716V (Florida), and V717I (London)] and PS1 (M146L and L286V) that 
indicates the rapid onset of AD pathology and behavioral decline38-40. In a fashion similar to APP/PS1 
mice, 5XFAD mice treated with 1 (1 mg/kg/day; i.p.; 1 month; 4 months old) exhibited enhanced spatial 
learning and memory in the MWM test (Figure 1.4a and b). Moreover, the % area of 4G8-
immunoreactive amyloid plaques was diminished in the brains of 1-treated 5XFAD mice by ca. 40% 
compared to those of the vehicle-treated group (Figure 1.4c). In addition, the total, soluble, and 
insoluble levels of Aβ40 were lowered by ca. 40%, 20%, and 50%, respectively (as for Aβ42, ca. 30%, 
35%, and 20% decreases were observed, respectively). Levels of soluble oligomeric Aβ, recognized as 
toxic Aβ species41, were subject to a 30% reduction. The amount of congophilic amyloid plaques was 
also alleviated by 10%. Overall, our investigations with two AD transgenic mouse models demonstrate 
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Figure 1.4. Efficacies of 1 on Aβ species and cognitive defects in 5XFAD mice after the daily treatment 
of 1 or vehicle for 1 month (1 mg/kg/day; i.p.) at 4 months of age. (a) Escape latency time of vehicle- 
or 1-treated 5XFAD mice (vehicle or 1) and WT in the Morris water maze test. (b) Measurements of 
the crossing frequency and the time spend in target quadrant in the probe test. (c) Analysis of the 
amounts of 4G8-immunoreactive amyloid deposits measured from the hippocampal (hip), cortical (ctx), 
and thalamic (thl) areas of the brain in vehicle- or 1-treated 5XFAD mice (vehicle or 1). Scale bars = 
200 µm (white) and 500 µm (black). (d) Levels of total Aβ, soluble Aβ, insoluble Aβ, oligomeric Aβ 
and congophilic plaques in triplicate per sample. Animal number: (a and b) n = 17 for WT mice and n 
= 16 for vehicle- or 1-treated 5XFAD mice; (c and d) n = 16 for each group. The bars denote mean ± 
s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001 by unpaired t-test or ANOVA.  
 
 
1.2.3. Administration of 1 in APP/PS1 Mice Attenuates Neuroinflammation  
To determine whether the anti-inflammatory effects of 1 caused the decrease in the levels of Aβ species, 
microglia and astrocytes, the two major resident immune cells involved in the inflammatory response2,7, 
were histologically monitored using anti-Iba1 and anti-GFAP antibodies16 in the brains of APP/PS1 
mice (2 mg/kg/day, i.p.; 2 months; 7.5 months old). As shown in Figure 1.5a and b, the increased glial 
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activation in APP/PS1 mice, induced by chronic neuroinflammation, was reduced by 1. Activation of 
microglia in both the cortex and hippocampus was decreased by ca. 50% with the treatment of 1 
compared to vehicle-added APP/PS1 mice (note that the activation of astrocyte was lowered by ca. 
30%). In addition, the expression of pro-inflammatory markers (i.e., TNF-α, IL-1β, IL-6, and iNOS)16 
and immunoregulatory cytokine (i.e., IL-10)16, elevated in vehicle-treated APP/PS1 mice, was declined 
to levels comparable to those of WT mice upon administration of 1 in APP/PS1 mice (Figure 1.5c). On 
the other hand, the amounts of anti-inflammatory markers (i.e., IL-4, TGF-β, and Arg1)16, 
downregulated in APP/PS1 mice introduced with vehicle, were enhanced in the 1-treated group. 
Therefore, our histological and biochemical experiments support that 1 is able to lower the chronic 




Figure 1.5. Change in neuroinflammation upon treatment of 1 in wild-type (WT) and APP/PS1 mice. 
(a and b) Representative images and quantification of activated microglia (Iba1) and astrocyte (GFAP). 
Scale bars = 50 µm (c) Analysis of alteration in mRNA levels of pro- and anti-inflammatory cytokines 
after administration of 1 into WT mice (WT), vehicle-treated APP/PS1 mice (vehicle), and 1-treated 
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APP/PS1 mice (1). Pro-inflammatory marker: TNF-α, IL-1β, IL-6, and iNOS, Immunoregulatory 
cytokine: IL-10, Anti-inflammatory marker: IL-4, TGF-β, and Arg1. All data analysis was done at 9.5 
months of age. Animal number: (a-c) n = 4 for WT mice and n = 4 for vehicle- or 1-treated APP/PS1 




1.2.4. Anti-Neuroinflammatory Effects of 1 Originate from Microglia 
To identify the cellular source of 1’s anti-inflammatory activity, Aβ-induced alterations in the in vitro 
expression of inflammatory markers were first examined in three types of brain cells (i.e., microglia, 
astrocytes, and neurons) with and without the treatment of 1. The conditioned media (CM), containing 
a secreted mixture of diverse signaling mediators42, from these three types of cells were collected and 
treated to either astrocytes (CM from microglia) or microglia (CM from astrocytes or neurons). In the 
presence of Aβ42 (Figure 1.6a, top), microglia exhibited elevated levels of pro-inflammatory markers 
(i.e., TNF-α, IL-1β, IL-6, and iNOS)16 and immunoregulatory cytokine (i.e., IL-10)16, as well as reduced 
amounts of anti-inflammatory markers (i.e., IL-4, TGF-β, and Arg1)16, relative to the control (i.e., 
microglia without Aβ42 incubation). The concurrent introduction of 1 and Aβ42 to microglia could 
noticeably restore the expression of inflammatory markers to the levels comparable to those of the 
control (Figure 1.6a, top), indicating that 1 mitigated the Aβ-mediated inflammatory response in 
microglia. The CM from Aβ-treated microglia triggered an inflammatory response in astrocytes, 
evidenced by the changes in the expression of inflammatory markers (Figure 1.6a, bottom). Astrocytes 
incubated in the CM from 1-treated microglia expressed inflammatory markers at the levels comparable 
to those of the astrocytes incubated with the CM from the control group. 
In contrast, the direct treatment of 1 did not abate the Aβ-triggered inflammatory response in 
astrocytes (Figure 1.6b, top). The CM from astrocytes incubated with Aβ42 and 1 induced an 
inflammatory response in microglia (Figure 1.6b, bottom), suggesting that 1 could not divert the 
astrocyte-mediated modulation of inflammatory signaling in microglia. Moreover, 1 could not prevent 
Aβ-induced changes in the expression of neuronal ‘off’ signals (i.e., BDNF, CD47, and CD200) and a 
majority of the ‘on’ signals (i.e., CXCL10 and CCL21) (Figure 1.6c, top), responsible for sustaining the 
resting state and eliciting the activation of microglia, respectively16,43. Similar to the CM from Aβ-
treated neurons, the CM from 1-added neurons provoked an inflammatory response in microglia (Figure 
1.6c, bottom). Together, these observations indicate that 1 is capable of directly diminishing the Aβ-
induced inflammatory response of microglia among the three types of cells tested in this study. 
Moreover, through indirect effects prompted by microglia, 1 may be able to prevent the secondary 
inflammatory response in astrocytes. Thus, the anti-inflammatory effects of 1 could stem from its direct 





Figure 1.6. Identification of the responsible cells upon incubation of Aβ42 with and without 1. (a) 
Analysis of mRNA levels of inflammatory cytokines in microglia by treatment of Aβ42 species with and 
without 1 or in astrocytes [grown by transferring the conditioned media (CM) harvested from the 
microglia] (n = 3 independent experiments). (b) Measurement of mRNA levels of inflammatory 
cytokines in astrocytes upon addtion of Aβ42 species with and without 1 or in microglia (grown by 
transferring the CM harvested from the astrocytes) (n = 3 independent experiments). (c) Determination 
of mRNA levels of off/on signals in neurons with incubation of Aβ42 species with and without 1 or 
inflammatory cytokines in microglia (grown by transferring the CM harvested from the neurons) (n = 
3 independent experiments). Conditions: [Aβ42] = 10 µM; [1] = 10 µM; pro-inflammatory marker: TNF-
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α, IL-1β, IL-6, and iNOS; immunoregulatory cytokine: IL-10; anti-inflammatory marker: IL-4, TGF-
β, and Arg1; off signals: BDNF, CD4, and CD200; on signals: CXCL10, CCL21, and MMP3. *P < 
0.05; **P < 0.01 by One-way analysis of variance, Tukey’s post hoc test. All error bars indicate s.e.m. 
 
 
Table 1.1. Sequences of primer pairs. 
Genea Forward Reverse 
TNF-α 5’-GATTATGGCTCAGGGTCCAA-3’ 5’-GCTCCAGTGAATTCGGAAAG-3’ 
IL-1β 5’-CCCAAGCAATACCCAAAGAA-3’ 5’-GCTTGTGCTCTGCTTGTGAG-3’ 
IL-6 5’-CCGGAGAGGAGACTTCACAG-3’ 5’-TTGCCATTGCACAACTCTTT-3’ 
iNOS 5’-CACCTGGAACAGCACTCTCT-3’ 5’-CTTTGTGCGAAGTGTCAGTG-3’ 
IL-10 5’-AAGGCCATGAATGAATTTGA-3’ 5’-TTCGGAGAGAGGTACAAACG-3’ 
IL-4 5’-ATCCATTTGCATGATGCTCT-3’ 5’-GAGCTGCAGAGACTCTTTCG-3’ 
TGF-β 5’-TTACCTGGATGGAAGTGGAA-3’ 5’-TGTTATGAGGAAGGGGACAA-3’ 
Arg1 5’-AAGCCAAGGTTAAAGCCACT-3’ 5’-CGATTCACCTGAGCTTTGAT-3’ 
CXCL10 5’-AAAAGGGCTCCTTAACTGGA-3’ 5’-GCTGGTCACCTTTCAGAAGA-3’ 
CCL21 5’-AGCTATGTGCAAACCCTGAG-3’ 5’-CTCTTGAGGGCTGTGTCTGT-3’ 
MMP3 5’-GGGTAGGATGAGCACACAAC-3’ 5’-TAGAAGGAGGCAGCAGAGAA-3’ 
CD47 5’-TGGTATCCAGCAAGCCTTAG-3’ 5’-AAGACACCAGTGCCATCAAT-3’ 
BDNF 5’-AATTTGGTAAACGGCACAAA -3’ 5’-GCAAACAATCGCTTCATCTT-3’ 
CD200 5’-CAGGAACCCTTGATTGTGAC -3’ 5’-AGTTCCAGAGTCCCAGCTCT-3’ 
NEP 5’-GAAATTCAGCCAAAGCAAGC-3’ 5’-GATTTCGGCCTGAGGAATAA-3’ 
MMP9 5’-CCATGTCACTTTCCCTTCAC-3’ 5’-CTCACTAGGGCAGAAACCAA-3’ 
IDE 5’-GAAGACAAACGGGAATACCGTG-3’ 5’-CCGCTGAGGACTTGTCTGTG-3’ 
GAPDH 5’-TGAATACGGCTACAGCAACA-3’ 5’-AGGCCCCTCCTGTTATTATG-3’ 
 
aTNF-α, tumor necrosis factor-alpha; IL-1β, interleukin-1β; IL-6, interleukin-6; iNOS, inducible nitric oxide synthase; IL-10, 
interleukin-10; IL-4, interleukin-4; TGF-β, transforming growth factor-β; Arg1, arginase 1; CXCL10, chemokine (C-X-C 
Motif) ligand 10; CCL21, chemokine (C-C Motif) ligand 21; MMP3, matrix metallopeptidase 3; CD47, cluster of 
differentiation 47; BDNF, brain-derived neurotrophic factor; CD200, cluster of differentiation 200; NEP, neprilysin; MMP9, 
matrix metallopeptidase 9; IDE, insulin degrading enzyme; GAPDH, glyceraldehyde 3-phosphate dehydrogenase. 
 
 
1.2.5. 1 Promotes the Phagocytic Capacity of Microglia under Chronic Neuroinflammation 
The phagocytic capability of microglia poses an important aspect of the inflammatory response against 
external stimuli, such as Aβ, the persistent presence of which can induce chronic microglial activation2,7. 
With confirmation that the anti-inflammatory activity of the molecule originates from microglia (Figure 
1.6), the influence of 1 towards microglial phagocytosis, defective under AD-related pathological 
conditions7,16, was analyzed in vivo using confocal microscopy. Volumetric quantification of the 
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overlapping fluorescence regions through 3D reconstruction conferred a numerical representation of 
the microglial phagocytic process. 
Images of the brain slices co-immunostained with an anti-Iba1 antibody16 and ThS37 showed that 
Aβ-associated microglial recruitment was increased in 1-treated APP/PS1 mice (2 mg/kg/day, i.p.; 2 
months; 7.5 months old) compared to vehicle-treated APP/PS1 mice (Figure 1.7a). In order to examine 
the phagocytic aptitude of microglia more closely, Lamp1, a membrane protein expressed in microglial 
lysosomes16,44, was monitored, along with Iba1- and ThS-reactive amyloid plaques. Overlaying regions 
of the three fluorescence images presented the formation and location of Aβ-associated phagolysosomes, 
indicating the ongoing microglial phagocytosis of Aβ16,44 (Figure 1.7b). The treatment of 1 in APP/PS1 
mice increased the volumes of microglial phagolysosomes, Aβ-associated phagolysosomes, and 
microglia occupied by Aβ-loaded phagolysosomes by ca. 2.8, 1.3 and 2.3-fold, respectively, relative to 
those of vehicle-treated APP/PS1 mice (Figure 1.7b, bottom). 
Additionally, the morphology of microglia, closely related to its function16,45, was analyzed to 
confirm the effects of 1 on the phagocytic function of microglia. The amoeboid morphology of Aβ-
associated microglia in 1-treated APP/PS1 mice indicated that the compound could enhance the 
microglial phagocytosis of Aβ (Figure 1.7c). Quantification of the morphological parameters confirmed 
the transition of 1-incubated microglia towards its phagocytic state: treatment of 1 decreased microglial 
volume, dendrite length, and number of segments, terminal points, and branch points and increased cell 
body size (Figure 1.7c, bottom). Lastly, 1-administrated APP/PS1 mice exhibited increased levels of 
smaller Aβ species (< 25 µm) and decreased amounts of larger Aβ aggregates (25-50 µm, > 50 µm), 
compared to those of the vehicle-treated APP/PS1 mice (Figure 1.7d). Therefore, it can be inferred that 
the enhanced phagocytic capacity of 1-treated microglia led to an increase in the degradation of larger 
Aβ species. Overall, our immunohistological studies demonstrate that 1 can restore the phagocytic 
activity of microglia, defective in APP/PS1 mice16,46, evidenced by the increased co-localization of Aβ 
plaques and lysosomes within microglia, shifts in microglial morphology, and changes in the size 





Figure 1.7. Analysis of the microglial phagocytosis of Aβ and the activity of NLRP3 inflammasome-
related proteins in 1-treated APP/PS1 mice. (a) Colocalization of the microglia (Iba1, red) with Aβ 
aggregates (ThS, green) and quantification. Scale bars = 10 µm. 3D reconstruction from confocal image 
stacks. Scale bars = 10 µm. (b) Immunofluorescence images of Aβ aggregates (ThS, green) 
encapsulated within phagolysosome (Lamp1, blue) in microglia (Iba1, red) in the brains of vehicle- or 
1-treated APP/PS1 mice. Quantification of the microglial volume occupied by Lamp1(+) 
phagolysosomes, percent of the microglia containing Aβ-loaded phagolysosome, and Aβ encapsulated 
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in phagolysosomes. Low magnification scale bars = 40 µm; high magnification scale bars = 10 µm. 3D 
reconstruction from confocal image stacks. Scale bars = 10 µm. (c) Morphology of microglia (Iba1, red) 
surrounding Aβ (ThS, green) in the cortex of vehicle- or 1-treated APP/PS1 mice. Scale bars = 10 µm. 
3D reconstruction from confocal image stacks. (d) Morphometric analysis of Aβ plaques in vehicle- or 
1-treated APP/PS1 mice. (e) Effects of 1 on the activity of NLRP3 inflammasome-related proteins. 
Wild-type mice (WT), vehicle-treated APP/PS1 mice (vehicle), and 1-treated APP/PS1 mice (1). All 
data analysis was done at 9.5 months of age. Animal number: (a-d) n = 3 for vehicle- or 1-treated 
APP/PS1 mice; (e) n = 4 for WT mice and n = 4 for vehicle-treated or 1-treated APP/PS1 mice. *P < 
0.05; **P < 0.01 by Student’s t test or One-way analysis of variance, Tukey’s post hoc test. All error 
bars indicate s.e.m. 
 
 
1.2.6. 1 Downregulates the Constituent Proteins of NLRP3 Inflammasomes  
The NLRP3 inflammasome is a signaling mediator composed of NLRP3, ASC (apoptosis-associated 
speck-like protein containing CARD), and pro-caspase-122,47. Activated NLRP3 inflammasomes are 
responsible for cleaving pro-caspase-1 to produce caspase-1, which subsequently promotes the 
maturation of IL-1β, a representative pro-inflammatory cytokine47. Thus, the inhibition of NLRP3 
inflammasome activity has received attention as a promising strategy to diminish neuroinflammation in 
AD22,47. Previous research reported that acetaminophen suppressed the NLRP3 inflammasome pathway 
under pathological conditions48. To further comprehend 1’s anti-inflammatory activity, its influence on 
the expression of NLRP3 inflammasome-associated proteins, i.e., NLRP3, ASC, and IL-1β, in APP/PS1 
mice was investigated by gel electrophoresis and Western blot (gel/Western blot). As presented in Figure 
1.7e, 1 downregulated the production of NLRP3, ASC, and IL-1β. Moreover, a notable decrease in the 
ratio of cleaved caspase-1 to pro-caspase-1 was observed upon treatment of 1. These results suggest 
that the suppressed generation of NLRP3 and ASC by 1 may reduce the activation of caspase-1 and 
consequently IL-1β. Therefore, 1 may intervene in an upstream process which regulates the expression 
of NLRP3 and ASC. 
 
1.2.7. 1 Does Not Alter Aβ Aggregation and Aβ-Degrading Enzymes’ Expression 
To validate that the reduction of Aβ accumulation, observed in the brains of 1-treated AD transgenic 
mice, was indeed a product of 1’s anti-inflammatory activity over direct influence on a decrease in Aβ 
deposition, the modulating effects of the compound towards the aggregation pathways of Aβ40 and Aβ42, 
two major isoforms of Aβ49, and the expression of Aβ-degrading enzymes were probed in vitro and in 
vivo (WT and APP/PS1 mice), respectively. First, the effects of 1 towards inhibition of Aβ aggregate 
formation [inhibition experiment, Figure 1.8a (i)] and disassembly of preformed Aβ aggregates 
[disaggregation experiment, Figure 1.8a (ii)] were assessed through gel/Western blot and transmission 
electron microscopy (TEM). In both inhibition and disaggregation experiments, the Aβ species resulted 
from incubation with 1 did not exhibit noticeable changes in the size distribution and morphology, 
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relative to those generated without 1 (Figure 1.8b and c). In short, 1 does not modify the aggregation 
pathways of both Aβ40 and Aβ42. 
Moreover, the expression of enzymes responsible for Aβ degradation [i.e., neprilysin (NEP), 
matrix metallopeptidase 9 (MMP9), and insulin-degrading enzyme (IDE)] was analyzed in the brain 
samples of WT and vehicle- or 1-treated APP/PS1 mice. As depicted in Figure 1.8d, vehicle-treated 
APP/PS1 mice, compared to WT mice, indicated the reduced levels of NEP, MMP-9, and IDE, even 
with the administration of 1 (2 mg/kg/day, i.p.; 2 months; 7.5 months old). These observations indicate 
that 1 has no effect on the production of Aβ-degrading enzymes. Thus, our studies suggest the restored 
microglial phagocytic capacity via the treatment of 1 as the dominant to be responsible for alleviating 




Figure 1.8. Effects of 1 on the aggregation of Aβ and the expression of Aβ-degrading enzymes. (a) 
Scheme of the (i) inhibition and (ii) disaggregation experiments. (b) Visualization of the size distribution 
of the resultant Aβ40 and Aβ42 species from (i) and (ii) by gel/Western blot using an anti-Aβ antibody 
(6E10). Lanes: (C) Aβ40 or Aβ42; (1) Aβ40 or Aβ42 + 1. (c) TEM images of the samples obtained from 
(b, i). Scale bars = 200 nm. Conditions: [Aβ40 or Aβ42] = 25 µM; [1] = 50 µM; 20 mM HEPES, pH 7.4, 
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150 mM NaCl; 24 h; 37 °C; constant agitation. (d) Analysis of the levels of the enzymes (i.e., NEP, 
MMP9, and IDE) involved in Aβ degradation in wild-type mice (WT) and vehicle- or 1-administrated 
APP/PS1 mice (vehicle or 1). All data analysis was done at 9.5 months of age. Animal number: (d) n = 
4 for WT mice and n = 4 for vehicle- or 1-treated APP/PS1 mice. *P < 0.05 by One-way analysis of 




Dysfunction of microglia, a pivotal mediator of neuroinflammation, has been increasingly recognized 
as a causative factor in AD2; thus, developing chemical reagents capable of restoring microglial function 
is critically important and constitutes a promising but underexplored therapeutic strategy. We report that 
1 is the smallest synthetic neuroprotective agent known to date with the ability to promote microglial 
phagocytic function. The activity of 1 leads to effective attenuation of cognitive deficits in two types of 
AD transgenic mice (i.e., APP/PS1 and 5XFAD mice) and noticeable reduction of Aβ accumulation. 
Downregulation of the constituent proteins of NLRP3 inflammasomes (i.e., NLRP3 and ASC), 
witnessed in the brains of APP/PS1 mice administrated with 1, is most likely responsible for the rescue 
from microglial dysfunction. Our studies suggest that disrupting the malign neuroinflammatory cycle 
can improve cognitive impairment found in the AD-affected brain. Therefore, more specific approaches 
to regulate neuroinflammation in AD through the rectification of microglial dysfunction using small 
molecules are confirmed as a valid therapeutic approach against AD. Furthermore, neuroprotective 
small molecules capable of recovering microglial dysfunction with subsequent elevation of microglial 
phagocytic function could also serve as investigative tools to advance our understanding of the role of 
neuroinflammation in AD pathology. 
 
1.4. Experimental Section 
1.4.1. Materials and Methods  
All chemical reagents were purchased from commercial suppliers and used as received unless otherwise 
stated. Compound 1 was purchased from Alfa Aesar (Ward Hill, MA, USA) and characterized by a 
Bruker AVHD400 NMR spectroscopy [Korea Advanced Institute of Science and Technology (KAIST) 
Analysis center for Research Advancement (KARA), KAIST, Daejeon, Republic of Korea] and a 
micrOTOF-Q II mass spectrometer (HRMS; KARA). Aβ40 (DAEFRHDSG-
YEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV) and Aβ42 (DAEFRHDSGYEVHHQKLVFFAED-
VGSNKGAIIGLMVGGVVIA) were purchased from Anaspec (Fremont, CA, USA). HEPES [N-(2-
hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid)] was purchased from Sigma-Aldrich (St. Louis, 
MO, USA). The buffered solution was prepared in doubly distilled water [ddH2O; a Milli-Q Direct 16 
system (18.2 MΩ⋅cm; Merck KGaA, Darmstadt, Germany)]. Trace metal contamination was removed 
from the solutions used for the experiments by treating with Chelex (Sigma-Aldrich) overnight. The 
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absorbance in cell viability studies was measured by a SpectraMax M5e microplate reader (Molecular 
Devices, Sunnyvale, CA, USA). Metabolic stability assay to predict the half-life and clearance of 
compounds was evaluated with human liver microsomes [Daegu Gyeongbuk Medical Innovation 
Foundation (DGMIF), Daegu, Republic of Korea]. Analysis of the brain uptake of 1 in male CD1 mice 
was implemented at Shanghai ChemPartner (Shanghai, China). The concentration of Aβ was 
determined by an Agilent 8453 UV–Vis spectrophotometer (Santa Clara, CA, USA). The gel images 
were recorded on a ChemiDoc MP Imaging System (Bio-Rad, Hercules, CA, USA). Transmission 
electron microscopical images were obtained by a JEOL JEM-2100 transmission electron microscope 
[Ulsan National Institute of Science and Technology (UNIST) Central Research Facilities (UCRF), 
UNIST, Ulsan, Republic of Korea].  
 
1.4.2. Characterization of 1  
1H NMR [400 MHz, DMSO-d6, δ (ppm)]: 9.86 (s, 2H), 7.47 (s, 4H), 2.01 (s, 6H). 13C NMR [100 MHz, 
DMSO-d6, δ (ppm)]: 167.9, 134.6, 119.4, 23.9. HRMS: m/z Calcd for C10H12N2O2 [M + H]+: 193.0972; 
found: 193.0980. 
 
1.4.3. Cell Viability Studies  
The murine neuroblastoma Neuro-2a (N2a) cell line [American Type Cell Collection (ATCC), Manassas, 
VA, USA] was maintained in media containing 1:1 DMEM (GIBCO, Grand Island, NY) and opti-MEM 
(GIBCO), 5% (v/v) fetal bovine serum (FBS; Sigma-Aldrich), and 100 U/mL penicillin and 100 mg/mL 
streptomycin (GIBCO). The N2a cells were grown and maintained at 37 °C in a humidified atmosphere 
with 5% CO2. Cell viability upon treatment with 1 was determined by the MTT assay [MTT = 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]. The cells were seeded in a 96-well plate 
(10,000 cells in 100 µL per well). The cells were treated with 1 (10, 50, 100, 200, and 500 µM; 1% v/v 
final DMSO concentration) and incubated for 24 h. After incubation, MTT [25 µL; 5 mg/mL in 
phosphate buffered saline (PBS; pH 7.4)] was added to each well and the plate was incubated for 4 h at 
37 °C. Formazan produced by the cells was solubilized using an acidic solution of N,N-
dimethylformamide (DMF; 50% v/v, aq) and sodium dodecyl sulfate (SDS; 20% w/v) overnight at room 
temperature in the dark. The absorbance was measured at 600 nm by the microplate reader. Cell viability 
was calculated relative to cells containing an equivalent amount of DMSO. 
 
1.4.4. Metabolic Stability Assay  
1 (1 µM) was added into the PBS solution (0.1 M, pH 7.4) containing human liver microsomes (0.5 
mg/mL), and was incubated for 5 min at 37 °C. Dihydronicotinamide adenine dinucleotide phosphate 
(NADPH) regeneration system solution was introduced to the pre-incubated mixture and then incubated 
for 15, 30, and 60 min at 37 °C. To terminate the reaction, the acetonitrile (CH3CN) solution that 
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included chlorpropamide known as an internal standard was added. After a centrifugation (14,000 rpm, 
4 °C) for 5 min, the supernatant was injected for the analysis of 1 and its possible metabolites into the 
LC-MS/MS system (DGMIF). 
 
1.4.5. Brain Uptake Studies  
After 5 min administration of 1 in male CD1 mice (10 mg/kg; per os, p.o), the mice were manually 
restrained. Blood samples were taken from the animals via retro orbital puncture for semi-serial 
bleeding or cardiac puncture (under anesthesia with isoflurane) for terminal bleeding into K2EDTA 
tubes. Blood samples were put on ice and centrifuged to obtain plasma samples (2,000 g, 5 min under 
4 °C) within 15 min. The animal was euthanized with pure CO2 inhalation. A mid-line incision was 
made on the neck. The muscle under the skin was cut to expose the cisterna magna. The cisterna magna 
was penetrated with the sharp end of one capillary. The cerebrospinal fluid (CSF) would be sucked 
spontaneously into the capillary. After CSF collection, a mid-line incision was made in the animal’s 
scalp and skin retracted. The skull overlying the brain was removed. The whole brain was collected, 
rinsed with cold saline, dried on filtrate paper, weighed, and snap frozen by placing into dry ice. The 
supernatant diluted with H2O and methanol (CH3OH) of each sample (i.e., plasma, brain, and CSF) was 
injected for LC-MS/MS analysis (Shanghai ChemPartner). 
 
1.4.6. Animal and Drug Administration (APP/PS1 Mice)  
Transgenic mice overexpressing the human APP695 [K670N/M671L (Swedish)] and PS1 (M146V) 
mutations were originated from GlaxoSmithKline (Harlow, UK)35 and maintained as previously 
described50. Because APP/PS1 mice show sex differences in disease progression, we used only male 
mice. Data analysis was done in 9.5 months of age. Age and sex matched C57BL/6 mice were used as 
WT mice. Block randomization method was used to allocate the animals to experimental groups. To 
eliminate the bias, we were blinded in experimental progress, such as data collection and data analysis. 
Mice were housed at a 12 h day/12 h night cycle with free access to tap water and food pellets. All 
protocols were approved by the Kyungpook National University Institutional Animal Care and Use 
Committee (IACUC). 1 was freshly prepared shortly before treatment by dissolving it in vehicle [85% 
DMSO in saline], and injected intraperitoneally every morning for 2 months, at the dose of 2 mg/kg of 
body weight starting at 7.5 months of age. 
 
1.4.7. Behavioral Studies (APP/PS1 Mice)  
We performed behavioral studies to assess spatial learning and memory in the Morris water maze 
(MWM) as previously described16,50,51. Animals were given four trials per a day for 10 days to learn the 
task. At day 11, animals were given a probe trial in which the platform was removed. Fear conditioning 
was conducted following previously described techniques50. On the conditioning day, mice were 
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individually placed into the conditioning chamber. After a 60 s exploratory period, a tone (10 kHz, 70 
dB) was delivered for 10 s; this served as the conditioned stimulus (CS). The CS co-terminated with the 
unconditioned stimulus (US), a scrambled electrical footshock (0.3 mA, 1 s). The CS−US pairing was 
delivered twice at a 20 s intertrial interval. On day 2, each mouse was placed in the fear-conditioning 
chamber containing the same exact context, but with no administration of a CS or foot shock. Freezing 
was analyzed for 5 min. On day 3, a mouse was placed in a test chamber that was different from the 
conditioning chamber. After a 60 s exploratory period, the tone was presented for 60 s without the 
footshock. The rate of the freezing response of mice was used to measure the fear memory. The open 
field test was used for locomotion and anxious behaviors as previously described16. The open field box 
consisted of a square box. Each animal was placed in the box for 10 min. Overall activity in the box 
was measured, and the amount of time and distance traveled in the center arena was noted. After each 
trial, the test chambers were cleaned with a damp towel and ddH2O followed by ethanol (EtOH, 70% 
v/v). The light and dark test was used for assessing the anxiety-like behavior as previously described16. 
One chamber was brightly illuminated, whereas the other chamber was dark. Mice were placed into the 
dark chamber and allowed to move freely between the two chambers with the door open for 10 min. 
The total number of transitions, latency to first enter the light chamber, distance traveled, and time spent 
in each chamber were recorded. 
 
1.4.8. Histological Analysis (APP/PS1 Mice)  
Mice anesthetized were transcardially perfused with PBS to wash out the residual blood from cerebral 
circulation. After perfusion with PBS, mice were further perfused with 4% paraformaldehyde (PFA) in 
PBS. Brains were post-fixed in 4% PFA overnight at 4 °C. Brain tissue was then coronal sectioned at a 
thickness of 30 µm using a vibratome. Thioflavin-S (ThS) staining was carried out according to 
previously described procedures51. We used Iba1 (rabbit, 1:500, 019-19941; Wako Pure Chemical 
Industries, Ltd., Osaka, Japan), GFAP (rabbit, 1:500, N1506; Dako, CA, USA), and Lamp1 (mouse, 
1:200, ab24170; Abcam, Cambridge, UK). The sections were analyzed with a laser-scanning confocal 
microscope (FV1000; Olympus, Tokyo, Japan) or with a BX51 microscope (Olympus). MetaMorph 
software (Molecular Devices) was used for quantification. Three-dimensional reconstruction of 
microglia was recorded and analyzed using IMARIS software (Bitplane, Belfast, UK)52. 
 
1.4.9. Animal and Drug Administration (5XFAD Mice) 
For evaluation of 1’s in vivo efficacy in the AD affected brain, we treated 5XFAD mice, a transgenic 
animal model of AD overexpressing mutant human APP695 [K670N/M671L (Swedish), I716 V 
(Florida), and V717I (London)] and PS1 (M146L and L286V)38, with 1 as previously described39,40. 
Mice were housed at a 12 h day/12 h night cycle with free access to tap water and food pellets. Animal 
studies with 5XFAD mice were conducted in accordance with the guidelines of the Asan Institute for 
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Life Science for Laboratory Animal Care and Use (Asan Medical Center, Seoul, Republic of Korea). 1 
was freshly prepared shortly before treatment by dissolving it in vehicle [1% DMSO v/v; 20 mM 
HEPES, pH 7.4, 150 mM NaCl], and injected intraperitoneally every morning for consecutive 31 days, 
at the dose of 1 mg/kg of body weight starting at 3 months of age. 
 
1.4.10. Behavioral Studies (5XFAD Mice) 
From the 27th day of the treatment, the performance of spatial learning and memory of the animals was 
assessed in the MWM with three test trials per a day for 5 days39,40. The mice also experienced the probe 
trials for 60 s in the MWM without the target platform at 3 h after the last MWM test. The test 
parameters were collected and analyzed on the SMART Video Tracking System (Harvard Apparatus, 
Holliston, MA, USA). 
 
1.4.11. Histological Analysis (5XFAD Mice) 
The deposition of amyloid plaques was assessed on the sagittal sections (12 µm thickness) of the left 
hemispheres after the immunohistochemistry and histological staining using the human Aβ(17-24)-
specific antibody 4G8 (Covance, Princeton, NJ, USA) and Accustain® Congo Red amyloid staining 
solution (Sigma-Aldrich), respectively. The stained sections were examined or photographed under a 
light microscope (Eclipse 80i; Nikon, Tokyo, Japan). Amyloid deposits were presented as the percent 
area of 4G8-immunoreactive deposits or the number of congophilic plaques per mm2 of the brain 
regions.  
 
1.4.12. Enzyme-Linked Immunosorbent Assay (ELISA) for Quantification of the Cerebral Aβ 
(5XFAD Mice)  
Amyloid pathology was evaluated as previously described39,40. Aβ40, Aβ42 (Invitrogen, Carlsbad, CA, 
USA), and oligomeric Aβ (Biosensis, Thebarton, Australia) were measured in PBS-, SDS-, or formic 
acid (FA)-soluble fractions following the serial centrifugal fractionations of the right cerebral 
hemispheres by sandwich ELISA.  
 
1.4.13. Primary Cell Culture  
Neurons from E18 C57BL/6 mice were prepared as previously described with minor modifications53. 
Cortices were dissected and then dissociated followed by incubation in papain for 15 min at 37 °C. 
Neurons were plated on poly-L-lysine-coated coverslips with neuronal culture medium, serum-free 
Neurobasal medium (GIBCO) containing 2% B27 supplements (GIBCO), 1 mM Glutamax supplement 
(GIBCO), and 100 U/mL penicillin and 100 mg/mL streptomycin (GIBCO) at 37 °C in a humidified 
atmosphere of 5% CO2. Primary astrocyte cultures were prepared from C57BL/6 mice as previously 
described54. In brief, after removal of the meninges, postnatal day 7 (P7) mouse brain tissues were 
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minced and incubated in a rocking water bath at 37 °C for 30 min in the presence of 0.25% trypsin-
EDTA (Sigma-Aldrich). Enzyme-digested dissociated cells were triturated with astrocyte-specific 
medium (DMEM/F12 containing 10% FBS, 0.2 and 1% penicillin-streptomycin) and centrifuged at 
1,300 rpm for 8 min. The pellet was resuspended in DMEM/F12, passed through a 40-µm cell strainer. 
The filtrate was allowed for pre-adherence for 30 min to remove any contamination from fibroblasts 
before being seeded in dishes and added the astrocyte-specific medium. For astrocytes splitting, dishes 
were added with Ara-C and placed in a heated shaker for 6-7 h. The medium was removed from the 
dishes, and trypsin-EDTA was added to the dish and incubated for 5-10 min at 37 °C. After 
centrifugation at 1,300 rpm for 8 min, the supernatant was removed and the astrocytes were maintained 
in culture by feeding every 1-2 weeks with astrocyte-specific medium. Primary microglia were isolated 
from the mice brain as previously described55. The cortex of WT (1-month-old) mice were minced in 
the Hibernate A (GIBCO)/B27 (Invitrogen) medium and dissociated using papain (Worthington 
Biochemical Corporation, NJ, USA) solution. After tissue trituration, cells were separated by Optiprep 
(Sigma-Aldrich) density gradient centrifugation. Fractionated microglia were cultured in DMEM/F12 
containing 10% FBS, 0.2 and 1% penicillin-streptomycin. We confirmed the successful isolation of 
primary cells from the brains of mice following each published methods53,54,55. 
 
1.4.14. Aβ-Mediated Inflammatory Response in Various Cells  
Aβ42 (Invitrogen) was solubilized in 10% DMSO, to a stock concentration of 500 µM. The Aβ42 solution 
was then incubated at 37 °C for 7 days to produce aggregated forms (i.e., containing oligomeric and 
fibrillar Aβ). To examine inflammatory responses in vitro, Aβ42 (10 µM) was treated in microglia or 
astrocytes with and without 1 (10 µM). After 24 h, the CM derived from microglia or astrocytes was 
discarded, and the fresh medium was added into each cell. One day later, microglia or astrocytes were 
collected for analysis of inflammatory cytokines and the CM derived from microglia or astrocytes was 
transferred to the astrocytes (CM derived from microglia) or microglia (CM derived from astrocytes). 
After 24 h, astrocytes or microglia were collected for analysis of inflammatory cytokines. To investigate 
the effects of Off/On signals derived from neuron to microglia, neurons were treated with Aβ42 (10 µM) 
or Aβ42 (10 µM) with 1 (10 µM). After 24 h, the CM derived from neurons was discarded, and fresh 
medium was added into the neurons. One day later, neurons were collected to analyze for Off/On signals 
and the CM derived from neurons was transferred to the microglia. After 24 h, microglia were collected 
for analysis of inflammatory cytokines.  
 
1.4.15. Western Blotting for NLRP3-Related Protein Experiments  
Brain samples were lysed in RIPA buffer (Cell Signaling Technology, MA, USA), then subjected to 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a 
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nitrocellulose membrane. Membranes were blocked with 5% milk, incubated with a primary antibody 
and then incubated with an appropriate horseradish peroxidase-conjugated secondary antibody50. 
Primary antibodies to the following proteins were used: NLRP3 (rabbit, 1:1,000; 15101, Cell Signaling 
Technology), ASC (rabbit, 1:1,000; 67824, Cell Signaling Technology), Caspase 1 (mouse, 1:1,000; 
AG-20B-0042, Adipogen Life Sciences, CA, USA), IL-1β (mouse, 1:1000; 12242, Cell Signaling 
Technology), and β-actin (1:1,000; SC-47778, Santa Cruz Biotechnology, TX, USA). Rabbit-HRP 
(1:1,000; 7074s, Cell Signaling Technology) and mouse-HRP (1:1,000; sc2005, Santa Cruz 
Biotechnology) were used as the secondary antibody. We performed densitometric quantification using 
the ImageJ software (National Institutes of Health, ME, USA). Images have been cropped for 
presentation. 
 
1.4.16. Aβ Aggregation Experiments  
All experiments were preformed according to previously published methods39,40,56. Prior to experiments, 
Aβ peptides were dissolved in ammonium hydroxide (NH4OH, 1% v/v aq), aliquoted, lyophilized 
overnight, and stored at -80 °C. A stock solution of Aβ was prepared by dissolving lyophilized peptide 
in 1% NH4OH (10 µL) and followed by dilution in ddH2O. The concentration of Aβ was determined by 
measuring the absorbance of the solution at 280 nm (ε = 1450 M−1cm−1 for Aβ40; ε = 1490 M−1cm−1 for 
Aβ42). The buffered solution (20 mM HEPES, pH 7.4, 150 mM NaCl) was used for preparation of Aβ 
samples. For the inhibition studies, 1 (50 µM) was added to a solution containing Aβ (25 µM) and 
incubated for 24 h at 37 °C with constant agitation (250 rpm). For the disaggregation studies, Aβ was 
incubated for 24 h at 37 °C with constant agitation prior to treatment with 1 (50 µM). The resulting 
samples containing Aβ (pre-incubated for 24 h) and 1 were incubated for an additional 24 h at 37 °C 
with constant agitation. 
 
1.4.17. Gel Electrophoresis and Western Blotting  
The Aβ samples from the inhibition and disaggregation experiments were analyzed by gel/Western blot 
utilizing an anti-Aβ antibody (6E10) following previously reported procedures39,40,56. Samples (10 µL) 
were separated on a 10-20% Tris-tricine gel (Invitrogen). Following separation, the proteins were 
transferred onto nitrocellulose membranes, which was blocked with bovine serum albumin (BSA, 3% 
w/v, RMBIO, Missoula, MT, USA) in Tris-buffered saline (TBS) containing 0.1% Tween-20 (TBS-T) 
for 4 h at room temperature or overnight at 4 °C. The membranes were incubated with 6E10 (1:2000, 
Covance) in a solution of 2% BSA (w/v in TBS-T) for 4 h at room temperature or overnight at 4 °C. 
After washing with TBS-T three times (10 min each), the horseradish peroxidase-conjugated goat anti-
mouse secondary antibody (1:5000, Cayman Chemical Company, Ann Arbor, MI, USA) in 2% BSA 
23 
was added for 2 h at room temperature. A homemade ECL kit39,40,56 was then used to visualize the results 
on a ChemiDoc MP Imaging System (Bio-Rad). 
 
1.4.18. Transmission Electron Microscopy 
Aβ40 samples for TEM measurements were prepared following previously reported methods39,40,56. 
Glow discharged grids (Formvar/Carbon 300-mesh, Electron Microscopy Sciences, Hatfield, PA, USA) 
were treated with the samples (5 µL) of (i) compound-free Aβ40 aggregates and (ii) Aβ40 aggregates 
incubated with 1 for 2 min at room temperature. Excess sample was removed with filter paper and the 
grids were washed with ddH2O three times. Each grid was stained with uranyl acetate (1% w/v ddH2O; 
5 µL) for 1 min. Uranyl acetate was blotted off and grids were dried for at least 20 min at room 
temperature. Images of samples were obtained by a JEOL JEM-2100 transmission electron microscope 
(200 kV; 25,000x magnification; UCRF). For the TEM studies, we randomly picked the locations of 
samples on the grids for taking images and collected more than 20 images from each grid.  
 
1.4.19. RNA Isolation and Real-Time PCR Analysis  
RNA was extracted from brain homogenates and cell lysates using the RNeasy Lipid Tissue Mini kit 
and RNeasy Plus Mini kit (QIAGEN, Hilden, Germany) according to the manufacturer’s instructions. 
cDNA was synthesized from 5 µg of total RNA using a commercially available kit (Takara Bio Inc., 
Shiga, Japan). Quantitative real-time PCR was performed using a Corbett research RG-6000 real-time 
PCR instrument. The used primers in this study are described in Supplementary Table 1. 
 
1.4.20. Statistics  
Sample sizes were determined by G-Power software (with α = 0.05 and power of 0.8). In general, 
statistical methods were not used to re-calculate or predetermine sample sizes. Variance was similar 
within comparable experimental groups. Experimenters were blinded to the identity of experimental 
groups until the end of data collection and analysis for at least one of the independent experiments. 
Comparisons between two groups were performed with Student’s t-test. In cases where more than two 
groups were compared to each other, an One-way analysis of variance (ANOVA) was used, followed 
by Tukey’s HSD test or Student-Newman-Keuls post hoc test. All statistical analyses were performed 
using SPSS statistical software. All values were denoted as mean s.e.m. Statistical difference was 
considered significant at *P < 0.05, **P < 0.01, ***P < 0.001. 
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Alzheimer's disease (AD), a chronic neurodegenerative disease, is characterized by the accumulation 
of amyloid-β (Aβ) deposits in the brain1-3. Aβ deposits are mainly composed of the aggregates of two 
isoforms, Aβ40 and Aβ422,3. Upon peptide aggregation, various Aβ aggregates, including oligomers, 
protofibrils, and fibrils, are generated showing their distinct biological properties (e.g., toxicity)4-6. 
Among Aβ aggregates, several studies indicate that oligomers and fibrils are involved in toxicity5,7-10. 
Thus, effective tactics to identify Aβ aggregates have been recently developed. Along with thioflavin-
T (ThT), a widely used probe for sensing β-sheet-rich Aβ aggregates11, emissive probes for optical 
sensing and imaging of Aβ deposits have been devised to evaluate and monitor the progression of AD12-
32. Effective emissive probes for Aβ deposits should possess emission wavelength in the near-infrared 
(near-IR) region for having less photo-induced damage of cellular components and for minimizing the 
background fluorescence from the brain tissue16-27. 
Chemical probes containing donor-π-acceptor and donor-π-acceptor-π-donor systems, such as 
AOI987, CRANAD-2, NIAD-4, and SN2, were developed for the detection of Aβ plaques with near-
IR fluorescent signals15,16,18,19,27,31,32. To construct the electron push-pull models, the design utilized the 
structures of 4-methylmorpholine, dimethylaminostyrene, and phenol as the donors as well as the 
difluoroboronate, pyrone, and dicyano groups as the acceptors15,16,18,19,27,31,32. Fluorescent probes 
containing a donor-π-acceptor system, composed of a dimethylaminostyrene group and a conjugated 
linker between the donor and acceptor, were reported to have a nanomolar range of the binding affinity 
(Kd) for Aβ fibrils15,19,27. Although they showed some changes in fluorescence upon binding to Aβ fibrils, 
the emission maximum of the probes ranged from 504 nm to 661 nm15,19,27. 
Herein, we report a turn-on near-IR fluorescent probe (2; Scheme 2.1) capable of detecting Aβ 
aggregates upon the progression of Aβ aggregation at ca. 710 nm. Our probe, 2, is composed of a π-
conjugated bridge between dimethylaminostyrene and benzo[e]indole groups. Although a sensor having 
a similar structure was previously reported for another purpose (i.e., detection of SO32− and 
SO42−/HSO4−)33, 2 was evaluated in the present study as a probe capable of detecting Aβ aggregates 
based on fluorescence at the distinctly separated near-IR region. Our non-emissive probe, 2, exhibits 
turn-on fluorescence upon incubation with Aβ aggregates. In addition, the fluorescence intensity of 2 
was varied based on the aggregation states of Aβ, suggesting the utility of the probe in monitoring Aβ 
aggregation. Furthermore, 2 presents turn-on fluorescence with Aβ aggregates in living cells, along with 











2.2. Results and Discussion 
2.2.1. Design and Synthesis of Probe 2 
The styrene-based fluorescence probe, 2, was designed for imaging Aβ aggregates and prepared as 
shown in Scheme 2. The structure of 2 contains (i) the dimethylamino functionality as an Aβ-interacting 
moiety17 and an electron donor and (ii) the benzo[e]indole group as an electron acceptor. Such an 
electron donor-acceptor unit in the conjugation system leads to decreasing the non-radiative decay rate 
and consequently increasing the emission intensity due to the hindrance of the internal molecular 
rotation of the probe42. In addition, to gain fluorescent signals at the near-IR region, the length of the π-
conjugation was adjusted. The synthesized compound, 2, was confirmed by NMR spectroscopy and 
mass spectrometry (Figure 2.1). 
 
 
Figure 2.1. 1H NMR spectrum of 2 in DMSO‑d6. 
 
2.2.2. Fluorescent Responses of 2 to Aβ Aggregates 
In an organic solvent (i.e., CH3CN), the absorption and emission bands of 2 were observed at 568 nm 
and 690 nm, respectively (Figure 2.2). The probe displayed the absorption bands at 479 and 589 nm 
and the emission peak at ca. 700 nm in a buffered solution (pH 7.4) (Figure 2.2 and 2.3). As expected 
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from the longer conjugation linker of the probe (Scheme 2.1), the absorption and emission wavelengths 




Figure 2.2. Absorption (a) and emission (b) spectra of 2 in the buffered solution (red) and CH3CN 
(black). Conditions: [2] = 2 µM; 10 mM PBS buffer, pH 7.4; λex = 600 nm.  
 
 
Figure 2.3. Absorption and emission spectra of 2. Conditions: [2] = 3 µM; 10 mM PBS buffer, pH 7.4; 
λex = 600 nm. 
 
Since Aβ peptides have different aggregation states and multiple polymorphs (e.g., monomers, 
oligomers, and fibrils) during their aggregation pathways following the phases of lag, elongation, and 
plateau4,7,43,44, the ability of fluorescent probes to detect Aβ could be varied depending on the type of 
peptide aggregates14-27,45-49. To determine the fluorescent response of 2 to a variety of Aβ species, 
including monomers, oligomers, or fibrils, Aβ species prepared at different incubation time points were 
treated with the probe (Figure 2.4). In the buffered solution (pH 7.4), the fluorescence intensities of 2 
were noticeably elevated at ca. 710 nm with excitation at 574 nm in the presence of Aβ aggregates (10 
equiv), in contrast to the weak fluorescence in the absence of Aβ (Figure 2.4a and b; black). In detail, 
the fluorescence intensity of 2 was gradually increased with treatment of Aβ40 species generated upon 
aggregation (up to 5 h pre-incubation; Figure 2.4a, left) and decreased with Aβ40 aggregates produced 
upon longer incubation, 10 and 12 h incubation (Figure 2.4a, right). In the case of Aβ42, 2 exhibited the 
change in fluorescence, similar to Aβ40 species (Figure 2.4b). 2 displayed the enhanced fluorescence 
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with aggregated Aβ [in particular, Aβ aggregates produced by 3-5 h incubation rather than those by 12 
h incubation (larger aggregates) (vide infra)]. 
 
 
Figure 2.4. Fluorescent responses of 2 to the aggregates of (a) Aβ40 and (b) Aβ42. Conditions: [Aβ] = 
20 µM; [2] = 2 µM; 20 mM HEPES, pH 7.4, 150 mM NaCl; 10 min incubation of 2 with Aβ species 
prior to measurements; λex = 574 nm; experiments were conducted in triplicate. 
 
 
To confirm that the change in fluorescence of 2 resulted from the interaction with Aβ aggregates 
over other possibilities, such as the self-assembly of the probe through π-stacking, its fluorescence at 
different concentrations was measured. The fluorescence intensity of 2 was enhanced proportionally as 
a function of its concentration (0.5-3.0 µM) in the absence of Aβ peptides (Figure 2.5), indicating that 
the emerged fluorescence of the probe was mainly from the interaction with Aβ aggregates and was not 
be from its self-aggregating effect. Moreover, to identify that 2 behaves as a molecular rotor, similar to 
ThT42,50, the fluorescence intensity of the probe was monitored as a function of the viscosity of the 
solution. As depicted in Figure 2.6, the fluorescence intensity of 2 was gradually increased as the 
amount of glycerol in a mixture of MeOH and glycerol was enhanced. This presents that the elevated 




Figure 2.5. Change in the fluorescence intensity of 2 at various concentrations. (a) Fluorescence spectra 
of 2 and (b) a plot of the integrated fluorescence of 2 as a function of its concentration. Conditions: [2] 




Figure 2.6. Absorption (a) and emission (b) spectra of 2 in a mixture of MeOH and glycerol with 
different ratios (MeOH:glycerol =1:0, 4:1, 3:2, 2:3, 1:4, and 0:1). Conditions: [2] = 2 μM; λex = 600 nm. 
 
 
2.2.3. Identification of Aβ Species Generated at Various Incubation Time Points 
To trace the preference of 2 towards the structures of Aβ aggregates generated during peptide 
aggregation, the kinetic of Aβ aggregation as well as the Aβ species produced following the incubation 
time were determined (Figure 2.7). The formation of β-sheet-rich aggregates of Aβ was investigated by 
the ThT assay (Figure 2.7a and d)11,34. In addition, the structural information of Aβ aggregates was 
obtained by the dot blot assay with three distinct antibodies, 6E10 (for Aβ species)54,55, A11 (for 
structured oligomeric Aβ)54, and OC (for fibrillar Aβ)54, as well as transmission electron microscopy  
(TEM) (Figure 2.7b, c, e, and f). In the case of Aβ40, the short lag phase of Aβ aggregation was observed 
(from 0 to 0.6 h) followed by the phases of elongation (0.6-2 h) and plateau (after 2 h) (Figure 2.7a). 
The increased fluorescence intensity of ThT implies that more β-sheet-rich Aβ aggregates are formed 
with longer incubation of the peptide11. Based on the dot blot assay, the gradual generation and 
maintenance of structured oligomers and fibrils were monitored from 0.6 to 10 h by A11 and OC, 
respectively (Figure 2.7b). After 10 h, the existence of fibrillar forms of Aβ40 was identified by OC; 
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however, less distinguishable dots were identified in Aβ40 samples by A11, suggesting that fewer 
amounts of structured oligomers may be present in the samples (Figure 2.7b). As the results by the ThT 
and dot blot assays indicated, more fibrils were recorded by TEM with longer incubation of Aβ40 (Figure 
2.7c). For Aβ42, its aggregation kinetic was similar to that of Aβ40, except for the shorter lag phase 
(Figure 2.7d). On the basis of the obtained data from the dot blot assay and TEM, as Aβ42 was incubated 
longer, more fibrils were detected, along with structured oligomers (Figure 2.7e and f). Taken both the 
results from the fluorescent responses of 2 to Aβ aggregates and the aggregation kinetics of Aβ peptides 






Figure 2.7. Aggregation kinetics and conformations of Aβ40 and Aβ42. The aggregation of Aβ40 (top) 
and Aβ42 (bottom) was identified by (a and d) the ThT assay, (b and e) the dot blot assay, and (c and f) 
TEM. Conditions: [Aβ] = 20 μM; 20 mM HEPES, pH 7.4, 150 mM NaCl; 37 °C; constant agitation; 




2.2.4. Detection Limit and Specificity of 2 towards Aβ Aggregates 
The detection limit and specificity of 2 for Aβ species were determined (Figure 2.8). Below the 0.5 
equiv of pre-incubated (5 h) Aβ species to 2 (2 µM), no distinguishable change in fluorescence was 
indicated (Figure 2.8a). On the other hand, the treatment of 2 with one or higher equiv of Aβ species 
noticeably indicated an increase in fluorescence, suggesting that at least one equiv of Aβ is required for 
2 to monitor Aβ species under our experimental conditions (Figure 2.8a). In addition, the fluorescent 
response of 2 to ubiquitin, a non-amyloidogenic protein containing all secondary structures56, was 
measured to verify the probe's specificity towards the amyloidogenic peptide, Aβ (Figure 2.8b). 
Compared to the remarkable turn-on fluorescence of 2 for Aβ aggregates, its incubation with ubiquitin 
did not show the altered fluorescence (Figure 2.8b), indicating that our probe could be a sensor for Aβ 
aggregates. Moreover, the fluorescence quantum yield of 2 was determined in the presence and absence 
of Aβ42 aggregates with methylene blue as the standard in water (ΦF = 1.8 and 0.35, respectively). 
Furthermore, in order to validate if 2 could modify the structure of pre-formed Aβ aggregates 
during the measurement of its fluorescence, the morphologies of Aβ aggregates upon the treatment of 
the probe were observed by TEM. As shown in Figure 2.9, although the interactions between 2 and Aβ 
species were expected based on the varied fluorescence of the probe, the distinguishable morphological 
alteration of Aβ aggregates after incubation with 2 was not monitored. Therefore, our studies present 





Figure 2.8. Fluorescent responses of 2 towards (a) Aβ42 aggregates, generated by pre-incubation for 5 
h, and (b) ubiquitin. Conditions: [Aβ42] = 0.5, 1, 2, 5, and 10 µM; [ubiquitin] = 20 µM; [2] = 2 µM; 20 






Figure 2.9. Morphologies of Aβ aggregates upon treatment with 2. The TEM images of pre-incubated 
(0.3, 1, 1.3, 2, 5, and 10 h) Aβ40 (top) and Aβ42 (bottom) were obtained after 10 min incubation with 2. 
Conditions: [Aβ] = 20 µM; [2] = 2 µM; 20 mM HEPES, pH 7.4, 150 mM NaCl. Scale bars = 200 nm. 
 
 
2.2.5. Imaging of Aβ Aggregates by 2 in Living Cells 
To evaluate the ability of 2 to visualize Aβ species in biological environments, imaging of Aβ aggregates 
by 2 was carried out in 5Y cells (Figure 2.10). No perceptible fluorescence of 2 (λex = 594 nm, λem = 
670-770 nm) was shown in the absence of Aβ aggregates in 5Y cells. When the probe was added to the 
cells pre-treated with Aβ40 aggregates generated by pre-incubation for 5 h, a prominent increase in red 
fluorescence was monitored (Figure 2.10). Note that the extracellularly existing Aβ aggregates and 2 
were removed by washing with PBS twice before fixing the cells. The imaging data of 2 with Aβ40 
aggregates, shown in Figure 2.10, could result from both possibilities: (i) our probe was bound to 
intracellular Aβ aggregates within the cells; (ii) the assembly of Aβ aggregates with 2 was 
extracellularly produced and entered the cells. Overall, the imaging results suggest that our probe could 
present turn-on fluorescence with Aβ aggregates in living cells. 
Furthermore, the cytotoxicity of 2 was determined (Figure 2.11). The concentration of 2 (500 nM) 
used for imaging of Aβ aggregates was nontoxic [98 (±0.6)% of cell viability for 30 min incubation]. 
Additionally, the IC50 value of 2 in 5Y cells for 24 h incubation is 3.3 µM (IC50, the concentration that 
produces 50% cytotoxicity; Figure 2.11). Thus, our in vitro and cell imaging studies propose that 2 





Figure 2.10. Imaging of Aβ aggregates by 2 in living cells. Fluorescent response of 2 was detected upon 
30 min incubation with 5Y cells with and without Aβ40 aggregates that were generated for 5 h. 





Figure 2.11. Cytotoxicity of 2. Cell viability (%) of 5Y cells incubated with various concentrations of 
2 was calculated through the MTT assay. 2 was treated in 5Y cells and incubated for (a) 30 min and (b) 
24 h. The cell viability was determined relative to that of the cells treated with an equivalent amount of 
DMSO. Error bars indicate the standard error from four independent experiments. Conditions: [2] = 0.5, 




A fluorescent probe containing the groups of styrene and benzo[e]indole was designed and prepared for 
detecting Aβ species. The fluorescent intensity of the probe, 2, was increased in the presence of the 
aggregates of both Aβ40 and Aβ42 at the near-IR region. According to the aggregation kinetics of Aβ, 
monitored by the probe, Aβ aggregates were visualized with a noticeable change in turn-on fluorescence. 
In addition to the aqueous solution, our probe was observed to be useful for visualizing Aβ aggregates 
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in living cells showing turn-on fluorescence. Therefore, our studies present the development and 
utilization of a near-IR fluorescent probe for indicating Aβ aggregates with turn-on 
signals. Our probe, however, is positively charged, which limits its blood-brain barrier permeability, 
similar to ThT31. To further advance the utility of such a probe towards Aβ aggregates in vivo 
(particularly, in the brain), we will design structurally modified or new probes with a neutral form, 
investigate their reactivities, and conduct their histological study, along with confirmation of utilization 
in biology in the near future. 
 
2.4 Experimental Section 
2.4.1. Materials 
All chemical reagents were purchased from commercial suppliers and used as received unless otherwise 
stated. Aβ40 (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV) and Aβ42 
(DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA) were purchased from Anaspec 
(Fremont, CA, USA). Ubiquitin (MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLI-
FAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG) was obtained from Sigma-Aldrich (St. Louis, MO, 
USA). HEPES [N-(2-hydroxyethyl)-piperazine-N'-(2-ethanesulfonic acid)] was purchased from Sigma-
Aldrich. The buffered solution containing 20 mM HEPES and 150 mM NaCl was prepared in doubly 
distilled water [ddH2O; a Milli-Q Direct 16 system (18.2 MΩ cm; Merck KGaA, Darmstadt, Germany)]. 
Trace metal contamination was removed from the solutions by treating with Chelex (Sigma-Aldrich).  
 
2.4.2. Synthesis of 2 (2-((1E,3E)-4-(4-(dimethylamino)phenyl)buta-1,3-dien-1-yl)-1,1,3-trimethyl-
1H-benzo[e]indol-3-ium iodide)  
To a solution of 4-(dimethylamino)-cinnamaldehyde (1.5 mmol) and 1,1,2,3-tetramethyl-1H-
benzo[e]indole iodide (1.5 mmol) in ethanol, piperidine (40 µL) was added and the reaction mixture 
was refluxed for 4 h. After cooled down to room temperature, the solution was treated with diethyl ether. 
The resulting precipitate was filtered and washed with ethanol and diethyl ether and dried in vacuum 
(508 mg; yield 80%). 1H NMR (400 MHz; DMSO‑d6; ppm): 1.95 (s, 6H), 3.08 (s, 6H), 4.02 (s, 3H), 
6.84 (d, J = 8.9 Hz, 2H), 7.03 (d, J = 15.0 Hz, 1H), 7.31 (t, J = 11.2 Hz, 1H), 7.60 (d, J = 8.9 Hz, 2H), 
7.66 (t, J = 8.1 Hz, 1H), 7.72-7.78 (m, 2H), 8.00 (d, J = 8.9 Hz, 1H), 8.17 (d, J = 8.1 Hz, 1H), 8.23 (d, 
J = 8.9 Hz, 1H), 8.34-8.41 (m, 2H). 13C NMR (125 MHz; DMSO‑d6; ppm): 26.5, 39.8, 40.1, 53.3, 181.0, 
160.9, 160.7, 155.6, 153.4, 151.9, 140.3, 137.2, 133.3, 132.0, 131.3, 130.7, 151.9, 127.6, 127.1, 124.6, 
123.8, 122.0, 113.5, 112.6, 111.9. MALDI-TOF (m/z): Calcd. for C27H29N2 + 381.23. Found 381.25. 
Anal.Calcd. for C27H29N2I: C, 63.78%, H, 5.75%, N, 5.51%. Found C, 63.93%, H, 5.70%, N, 5.41%. 
 
2.4.3. Absorption and Emission Measurements 
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The samples of 2 for absorption and emission measurements were prepared in 10 mM phosphate 
buffered saline (PBS) buffer (pH 7.4), acetonitrile (CH3CN), and the mixture of methanol (MeOH) and 
glycerol with different ratios. Absorbance spectra were collected using a PerkinElmer model Lambda 
2S UV–Vis spectrophotometer (PerkinElmer, Waltham, MA, USA) and an Agilent 8453 UV−Vis 
spectrophotometer (Santa Clara, CA, USA). Emission spectra were recorded on a PerkinElmer LS55 
fluorescence spectrometer (PerkinElmer) and a HORIBA PTI QuantaMaster 8000 fluorometer 
(HORIBA, Kyoto, Japan).  
 
2.4.4. Calculation of Quantum Yield 
The quantum yield of 2 was calculated using methylene blue as a reference. 
 





Where QYref is the quantum yield of the reference compound, η is the refractive index of the solvent, I 
is the integrated fluorescent intensity, and A is the absorbance at the excitation wavelength. Aβ peptides 
(0.5 mg/mL) were prepared in 10 mM PBS buffer, pH 7.4 and then incubated at 37 °C for 42 h with 
constant agitation.  
 
2.4.5. Preparation of Aβ Aggregates and Ubiquitin  
The concentrations of Aβ and ubiquitin were determined by an Agilent 8453 UV–Vis spectrophotometer. 
Aβ peptides were dissolved in hexafluoro-2-propanol (HFIP) and sonicated for 30 min. After 
evaporation of HFIP for 2 h, Aβ peptides were dissolved in NH4OH (1% v/v, aq; 10 µL) followed by 
dilution in ddH2O. Ubiquitin was dissolved in ddH2O. The concentration of each peptide was 
determined by measuring the absorbance of the solution at 280 nm (ε = 1450 M−1cm−1 for Aβ40; ε = 
1490 M−1cm−1 for Aβ42; ε = 1280 M−1cm−1 for ubiquitin). The solution of peptide was diluted to 20 mM 
with the buffered solution. The Aβ samples were incubated at 37 °C for various time points with 
constant agitation. 
 
2.4.6. Fluorescence Measurements with Aβ Aggregates 
The fluorescent responses of 2 (2 µM; 1% v/v DMSO) to (i) Aβ40 and Aβ42 species (20 µM), generated 
at incubation time points (0, 1, 1.3, 1.6, 2, 3, 5, 10, and 12 h); (ii) Aβ42 (0.5, 1, 2, 5, and 10 µM; 5 h 
incubation); (iii) ubiquitin (20 µM) were measured by a Varian CARY Eclipse fluorescence 
spectrophotometer [Ulsan National Institute of Science and Technology (UNIST) Central Research 
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Facilities (UCRF), UNIST, Ulsan, Republic of Korea] at λex = 574 nm with 10 min incubation prior to 
measurements.  
 
2.4.7. ThT Assay 
The kinetic of forming β-sheet-rich Aβ aggregates was monitored by the ThT assay34. ThT (20 µM) was 
treated with Aβ samples (20 µM) obtained after different incubation time points (0, 0.3, 0.6, 1, 1.3, 1.6, 
2, 3, 5, 10, and 12 h) at 37 °C with constant agitation. After 20 min, the fluorescence intensity of ThT 
(λex = 440 nm; λem = 490 nm) was measured by a SpectraMax M5e microplate reader (Molecular 
Devices, San Jose, CA, USA). 
 
2.4.8. Dot Blot Assay 
The solutions of Aβ aggregates (2 µL) were spotted on a nitrocellulose membrane, and the membrane 
was blocked with the solution of bovine serum albumin (BSA; 3% w/v; RMBIO, Missoula, MT, USA) 
in Tris-buffered saline containing 0.01% Tween 20 (TBS-T) at room temperature for 2 h. The membrane 
was incubated with a primary antibody, 6E10 (1:2000; Covance, Princeton, NJ, USA), A11 (1:1000; 
Invitrogen, Carlsbad, CA, USA), or OC (1:1000; Merck Millipore, Billerica, MA, USA), in the solution 
of BSA (2% w/v in TBS-T) for 2 h at room temperature. After washing with TBS-T (3×, 7 min), the 
horseradish peroxidase-conjugated goat anti-mouse (1:2000; for 6E10; Cayman Chemical Company, 
Ann Arbor, MI, USA) or goat anti-rabbit (1:2500; for A11 and OC; Promega, Madison, WI, USA) 
secondary antibody in the solution of BSA (2% w/v in TBS-T) was introduced to the membrane and 
incubated for 2 h at room temperature. A homemade ECL kit35-37 was used to visualize the results on a 
ChemiDoc MP Imaging System (Bio-Rad, Hercules, CA, USA). The same membrane was stripped by 
treating with hydrogen peroxide (H2O2) for 30 min at room temperature, washed with TBS-T (4×, 10 
min), blocked with the solution of BSA (3% w/v in TBS-T), and incubated with the other primary 
antibody (6E10, A11, or OC). 
 
2.4.9. Transmission Electron Microscopy  
Aβ samples for TEM measurements were prepared following previously reported methods35,36,38-40. 
Glow discharged grids (Formvar/Carbon 300-mesh, Electron Microscopy Sciences, Hatfield, PA,USA) 
were treated with the samples (5 µL) of (i) compound-free Aβ aggregates and (ii) Aβ aggregates 
incubated with 2 for 2 min at room temperature. Excess sample was removed with filter paper and the 
grids were washed with ddH2O (3×). Each grid was stained with uranyl acetate (1% w/v ddH2O; 5 µL) 
for 1 min. Uranyl acetate was blotted off and grids were dried for 20 min at room temperature. Images 
of samples were obtained by a JEOL JEM-2100 transmission electron microscope (200 kV; 25,000× 
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magnification; UCRF). The major species of Aβ aggregates are presented among collected images of 
sample. 
 
2.4.10. Live-Cell Fluorescence Imaging 
The human neuroblastoma SH-SY5Y (5Y) cell line [American Type Cell Collection (ATCC), Manassas, 
VA, USA] was maintained in media containing 1:1 Minimum Essential Media (MEM; GIBCO, Grand 
Island, NY, USA) and Ham's F12K Kaighn's Modification Media (F12K; GIBCO), 10% (v/v) fetal 
bovine serum (FBS; Sigma-Aldrich), and 100 U/mL penicillin and 100 mg/mL streptomycin (GIBCO). 
The 5Y cells were grown in a humidified atmosphere with 5% CO2 at 37 °C, seeded onto a plate at a 
density of 70,000 cells per 100 µL, and then incubated at 37 °C for 16 h. The 5Y cells were first treated 
with 2 [500 nM; final concentration of DMSO (1% v/v)] for 30 min without Aβ aggregates. The cells 
were washed with PBS (pH 7.4, GIBCO) twice. The cells were fixed with 4% formaldehyde and cold 
methanol41 and the fluorescence images were obtained. In the case of Aβ40, Aβ40 aggregates (5 µM) 
generated by pre-incubation for 5 h were treated to the cells for 1 h prior to the addition of 2 (500 nM). 
After 30 min incubation of 2, the cells were washed with PBS twice. After fixation, images were 
obtained by a confocal microscope Carl Zeiss LSM780 [Korea Advanced Institute of Science and 
Technology (KAIST) Analysis center for Research Advancement (KARA), KAIST, Daejeon, Republic 
of Korea]. The images were obtained by 561 nm laser with Alexa Fluor 594 detection channel with 
modification of emission collecting range from 670 to 770 nm (2.0% power; 1.58 µs as the pixel dwell; 
57 nm as the pinhole size; 63× objective). 
 
2.4.11. Cell Viability Studies 
Cell viability upon treatment with 2 was determined by the MTT assay. 5Y cells were seeded in a 96-
well plate (10,000 cells in 100 µL per well). The cells were treated with compounds (0.5, 1, 5, 10, 20, 
and 50 µM; 1% v/v final DMSO concentration) and incubated for 30 min and 24 h. After incubation, 
MTT [25 µL; 5 mg/mL in PBS (pH 7.4)] was added to each well and the plate was incubated for 4 h at 
37 °C. Formazan produced by the cells was solubilized using an acidic solution of N,N-
dimethylformamide (DMF; 50% v/v, aq) and sodium dodecyl sulfate (SDS; 20% w/v) overnight at room 
temperature in the dark. The absorbance was measured at 600 nm by a microplate reader.  
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Metal ions are essential components in our body for catalytic and structural functions in metalloenzymes, 
cellular signaling transmission, and metabolic process1,2. The distribution and concentration of metal 
ions are tightly regulated throughout cellular systems to maintain their homeostasis of biological 
systems1,3. Indeed, numerous studies have suggested that dysregulation of metal ions is significantly 
implicated in the pathogenesis of neurodegenerative diseases2,4,5. Highly concentrated metal ions can 
trigger the generation of reactive oxygen species which induce oxidative damage to cellular components, 
eventually leading to neuronal death2,4. Moreover, the elevated level of metal ions in the brain can 
attribute to accelerate the aggregation of proteins or inhibiting their enzymatic activities, inducing 
neurotoxicity4,6. To elucidate the complex metal-associated physiopathology in neurodegenerative 
diseases, effective techniques to provide information about metal-related biological events is necessary. 
Fluorescence-based detection of metal ions by chemical probes is a practical method to non-invasively 
indicate their local concentration and quantity in biological sytems7,8. In this Chapter, we evaluated the 
ability of the newly developed chemical probes capable of selectively responding to Al3+ and Zn2+ ions, 
respectively, with distinct fluorescence in living cells.  
 
3.2. Results and Discussion 
3.2.1. Detection of Al3+ Using the Probe, 3, in Living Cells 
A fluorescent sensor for Al3+, 3, was designed through the linkage of diethylaminophenol, as an electron 
donating group with high water solubility, and 2-furoic hydrazide, as a metal chelating moiety (Scheme 
3.1). The selective fluorescent response of 3 to Al3+ was monitored in an aqueous system at ca. 450 nm, 
and their photophysical property (e.g., stoichiometry and detection limits) and potential binding modes 
were determined. To assess the applicability of 3 as a sensor for Al3+ in biological environments, the 
fluorescent response of 3 was observed in HeLa cells in the absence and presence of Al3+. Prior to the 
introduction of 3, Al3+ (500 µM) was treated to HeLa cells followed by 20 min incubation. Without 3, 
any significant fluorescence was not exhibited in living cells. In contrast, a noticeable increase in 
fluorescence was observed upon treatment of 3 (25 µM) at the region of 4′,6-diamidino-2-phenylindole 
(DAPI) channel [λex = 357 (± 22) nm; λem = 447 (± 30) nm] (Figure. 3.1). These results demonstrate 3 
as a turn-on chemosensor for detecting Al3+ in biological systems.  
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Figure 3.1. Fluorescence imaging of HeLa cells incubated with 3 and Al3+. Cells were pre-incubated 
with Al3+ for 20 min prior to the addition of 3. Conditions: [3] = 25 µM, [Al3+] = 500 µM, 37 °C, 5% 
CO2. Scale bars = 50 µm. 
 
 
3.2.2. Detection of Zn2+ Using the Probe, 4, in Living Cells 
A new turn-on fluorescent probe for Zn2+, 4, was designed and synthesized. 4 showed the noticeable 
enhancement in fluorescence upon treatment of Zn2+ at ca. 520 nm, and its detection limits and the 
possible binding mode were identified in aqueous media (Scheme 3.2). To determine 4’s 
bioapplicability as a sensor for Zn2+ in living cells, the fluorescent response and cytotoxicity were 
measured in HeLa cells. When 4 (10 µM) was pre-incubated with living cells for 5 min followed by 
treatment with Zn2+ (1 mM), noticeable turn-on fluorescence was indicated at the range of green 
fluorescent protein (GFP) channel [λex = 470 (± 11) nm; λem = 510 (± 21) nm] (Figure 3.2). Under our 
imaging conditions ([4] = 10 µM; 5 min incubation), no toxicity of 4 was observed. These results 










Figure 3.2. Fluorescence imaging of HeLa cells incubated with 4 and Zn2+. Cells were incubated with 





Figure 3.3. Toxicity of 4 incubated in HeLa cells for (a) 5 min and (b) 24 h. 4 was treated to HeLa cells 
at various concentrations (5, 10, 20, and 50 µM; 1% v/v DMSO). Cell viability (%) was determined by 
the MTT assay [MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] in comparison 




3.2.3. Detection of Zn2+ Using the Probe, 5, in Living Cells 
A selective Zn2+ chemosensor based on benzofuran, 5, was newly designed and obtained. In aqueous 
media, 5 exhibited the distinct fluorescent response at ca. 530 nm to Zn2+ over other metal ions. The 
potential binding mode of 5−Zn2+ was determined through multiple spectroscopic and spectrometric 
studies (e.g., NMR, ESI-MS, and UV−Vis). In HeLa cells, 5 was pre-treated for 90 min prior to addition 
of Zn2+. In the presence of both 5 and Zn2+, a significant increase in fluorescence was observed in HeLa 
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cells. As the concentration of Zn2+ increased (0 to 1 mΜ), the clearer shape of cells was observed 










Figure 3.4. Fluorescence images of HeLa cells incubated with 5 followed by the addition of Zn2+. Cells 
were treated with 5 for 90 min prior to the introduction of Zn2+. Conditions: [5] = 25 µM; [Zn2+] = 0.5 




Metal ions play important biological roles in various functions in our body; thus, their dyshomeostasis 
is significantly contributed to the initiation and progression of neurodegeneration2,4,5. To effectively 
uncover the metal-associated pathogenesis of neurodegenerative diseases, many researchers have 
focused on the development of fluorescent probes to monitor metal ions in biological systems. In our 
studies, we newly developed and utilize the probes (i.e., 3, 4, and 5) for detecting each metal ion (i.e., 
Al3+ and Zn2+) in living cells. Further structural modifications will be carried out to improve high 




3.4. Experimental Section 
3.4.1. Imaging Experiments in Living Cells 
HeLa cells (ATCC, Manassas, VA, USA) were maintained in media containing Dulbecco’s Modified 
Eagle’s Medium (DMEM), 10% fetal bovine serum (FBS; Sigma-Aldrich), 100 U/mL penicillin and 
100 mg/mL streptomycin (GIBCO, Grand Island, NY, USA). The cells were grown in a humidified 
atmosphere containing 5% CO2 at 37 °C. Cells were seeded onto a 12-well plate (SPL Life Sciences 
Co., Ltd, Republic of Korea) and then incubated at 37 °C. Cells were treated with various concentration 
of Al(NO3)3 or Zn(NO3)2 (dissolved in water; 1% v/v final concentration) and probes (3, 4, or 5; in 
DMSO; 1% v/v final concentration). Imaging was obtained using an EVOS FL fluorescence microscope 
(Life Technologies) using a light cube of DAPI [λex = 357 (± 22) nm; λem = 447 (± 30) nm] or GFP [λex 
= 470 (± 11) nm; λem = 510 (± 21) nm]. 
 
3.4.2. Cell Viability Study of 4. 
HeLa cells were grown and maintained at 37 °C in a humidified atmosphere with 5% CO2. Cell viability 
upon treatment with 4 was determined by the MTT assay. Cells were seeded in a 96 well plate [(a) 8,000 
cells for 5 min incubation and (b) 1,500 cells for 24 h incubation in 100 mL per well]. Cells were treated 
with various concentrations 4 (5, 10, 20, and 50 µM). After 5 min or 24 h incubation, MTT [25 mL of 
5 mg/mL in PBS (pH 7.4, GIBCO)] was added to each well, and the plate was incubated for 4 h at 37 °C. 
Formazan produced by cells was solubilized using an acidic solution of dimethylformamide (DMF; pH 
4.5, 50% v/v, aq) and sodium dodecyl sulfate (SDS; 20% w/v) overnight at room temperature in the 
dark. The absorbance was measured at 600 nm by the microplate reader. Cell viability was calculated 
relative to cells containing an equivalent amount of DMSO. 
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